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This report focuses on patent landscape analysis of technologies related to prophylactic vaccines 
targeting pandemic strains of influenza.  These technologies include methods of formulating 
vaccine, methods of producing of viruses or viral subunits, the composition of complete 
vaccines, and other technologies that have the potential to aid in a global response to this 
pathogen.  The purpose of this patent landscape study was to search, identify, and categorize 
patent documents that are relevant to the development of vaccines that can efficiently promote 
the development of protective immunity against pandemic influenza virus strains. 
 
The search strategy used keywords which the team felt would be general enough to capture (or 
“recall”) the majority of patent documents which were directed toward vaccines against 
influenza A virus.  After extensive searching of patent literature databases, approximately 33,500 
publications were identified and collapsed to about 3,800 INPADOC families.  Relevant 
documents, almost half of the total, were then identified and sorted into the major categories of 
vaccine compositions (about 570 families), technologies which support the development of 
vaccines (about 750 families), and general platform technologies that could be useful but are not 
specific to the problems presented by pandemic influenza strains (about 560 families).  The first 
two categories, vaccines and supporting technologies, were further divided into particular 
subcategories to allow an interested reader to rapidly select documents relevant to the particular 
technology in which he or she is focused.  This sorting process increased the precision of the 
result set. 
 
The two major categories (vaccines and supporting technologies) were subjected to a range of 
analytics in order to extract as much information as possible from the dataset.  First, patent 
landscape maps were generated to assess the accuracy of the sorting procedure and to reveal the 
relationships between the various technologies that are involved in creating an effective vaccine.  
Then, filings trends are analyzed for the datasets.  The country of origin for the technologies was 
determined, and the range of distribution to other jurisdictions was assessed.  Filings were also 
analyzed by year, by assignee, and by inventor.  Finally, the various patent classification systems 
were mapped to find which particular classes tend to hold influenza vaccine-related technologies.  
Besides the keywords developed during the searches and the landscape map generation, the 






ThemeScape map of terms from influenza vaccine patent documents.  This category contained 
approximately 570 INPADOC patent families.  See Figure 10. 
 
 
The analysis included creation of a map of keywords, as shown above, describing the 
relationship of the various technologies involved in the development of prophylactic influenza A 
vaccines.  The map has regions corresponding to live attenuated virus vaccines, subunit vaccines 
composed of split viruses or isolated viral polypeptides, and plasmids used in DNA vaccines.  
Important technologies listed on the map include the use of reverse genetics to create reassortant 
viruses, the growth of viruses in modified cell lines as opposed to the traditional methods using 
eggs, the production of recombinant viral antigens in various host cells, and the use of 
genetically-modified plants to produce virus-like particles. 
 
Another major finding was that the number of patent documents related to influenza being 
published has been steadily increasing in the last decade, as shown in the figure below.  Until the 
mid-1990s, there were only a few influenza patent documents being published each year.  The 
number of publications increased noticeably when TRIPS took effect, resulting in publication of 
patent applications.  However, since 2006 the number of vaccine publications has exploded.  In 
each of 2011 and 2012, about 100 references disclosing influenza vaccine technologies were 




Publication trends for influenza vaccine documents.  Publications increased in the 1990s when 
patent applications began to be published, and then the numbers soared after outbreaks of H5N1 
and H1N1.  Similar results were observed with documents related to supporting technologies.  
See Figure 16. 
 
 
growing in recent years.  This interest is probably being driven by recent influenza outbreaks, 
such as the H5N1 (bird flu) epidemic that began in the late 1990s and the 2009 H1N1 (swine flu) 
pandemic. 
 
The origins of the vaccine-related inventions were also analyzed.  The team determined the 
country in which the priority application was filed, which was taken as an indication of the 
country where the invention was made or where the inventors intended to practice the invention.  
By far, most of the relevant families originated with patent applications filed in the United 
States.  Other prominent priority countries were the China and United Kingdom, followed by 
Japan, Russia, and South Korea.  France was a significant priority country only for supporting 
technologies, not for vaccines.  Top assignees for these families were mostly large 
pharmaceutical companies, with the majority of patent families coming from Novartis, followed 
by GlaxoSmithKline, Pfizer, U.S. Merck (Merck, Sharpe, & Dohme), Sanofi, and AstraZeneca.  
Governmental and nonprofit institutes in China, Japan, Russia, South Korea and the United 
States also are contributing heavily to influenza vaccine research.   
 
Lastly, the jurisdictions were inventors have sought protection for their vaccine technologies 






























Jurisdictions for filing applications and issuing patents related to influenza vaccines.  Filings in 
multi-jurisdictional agencies, such as ARIPO, the Gulf Cooperation Council, WIPO and the 
European Patent Office, are not shown.  The number of patent families is out of 570 total 
families.  See Figure 15 for a more detailed description. 
 
 
world map shown below.  The United States, Canada, Australia, Japan, South Korea and China 
have the highest level of filings, followed by Germany, Brazil, India, Mexico and New Zealand.  
However, although there are a significant number of filings in Brazil, the remainder of Central 
and South America has only sparse filings.  Of concern, with the exception of South Africa, few 
other African nations have a significant number of filings.   
 
In summary, the goal of this report is to provide a knowledge resource for making informed 
policy decisions and for creating strategic plans concerning the assembly of efficacious vaccines 
against a rapidly-spreading, highly virulent influenza strain.  The team has defined the current 
state of the art of technologies involved in the manufacture of influenza vaccines, and the 
important assignees, inventors, and countries have been identified.  This document should reveal 
both the strengths and weaknesses of the current level of preparedness for responding to an 
emerging pandemic influenza strain.  The effects of H5N1 and H1N1 epidemics have been felt 
across the globe in the last decade, and future epidemics are very probable in the near future, so 
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This educational report is neither inclusive nor comprehensive.  Rather, it is an informational 
resource intended to facilitate a better understanding of the international patent literature 
landscape regarding vaccines against influenza A viruses. 
 
This report is not a list of all potentially relevant patents.  Importantly, it is not a Freedom to 
Operate (FTO) opinion, but instead constitutes an educational analysis of potentially relevant 
material.  While the search platforms utilized in this project were extensive, none were 
comprehensive, and some countries and jurisdictions were underrepresented in the databases, 
either in the time frame covered, the availability of translated documents, and the completeness 
of the records.  Further, it is likely that the International Technology Transfer Institute (ITTI) 
team did not obtain the entire spectrum of relevant patents utilizing the various search strategies 
and methods articulated herein.  Therefore, the ITTI team does not guarantee that all relevant 
patents were discovered during the creation of this report. 
 
As the ITTI team members are not experts in the field of influenza A virus related vaccines, it is 
likely that the categorization of the patents found and coded are incomplete.  Further, many 
patent documents contain material relevant to multiple categories; the documents were placed in 
the category that the team, in its judgment, felt best represented the overall focus of the 
document.  The ITTI team cannot guarantee that the patents discovered were evaluated at the 
level of expert scientific sophistication.   
 
The limited time frame, competing academic demands, and the general press of business dictated 
the number of patents evaluated.  As such, additional patents may have been available that were 
not considered due to time constraints. 
 
Many names are capitalized and may or may not be trademarked and/or otherwise protected 





Abbreviations and Definitions  
 
Below is a list of abbreviations and definitions for terms and keywords used throughout the ITTI 
Fall 2012 report and the reported results. 
 
Adjuvants – defined herein as a substance sometimes included in a vaccine formulation to 




Antibody – defined herein as an infection-fighting protein molecule in blood or secretory fluids 
that tags, neutralizes, and helps destroy pathogenic microorganisms (e.g., bacteria, viruses) or 
toxins.  Antibodies, known generally as immunoglobulins, are made and secreted by B-
lymphocytes in response to stimulation by antigens.  Each specific antibody binds only to the 




Antibody-mediated immunity – defined herein as the immunity that results from the activity of 




Antigens - (immunogens; substances capable of provoking an immune response) – defined 
herein as foreign substances in the body that are capable of causing disease.  The presence of 
antigens in the body triggers an immune response, usually the production of antibodies.  
Antigens may be soluble substances, such as toxins and foreign proteins, or particulate, such as 
bacteria and tissue cells; however only the portion of the protein of polysaccharide molecule 





Anti-idiotype - herein defined as a manufactured antibody (Ab2) that can recognize the idiotype 
of another antibody (Ab1).  Theoretically, the anti-idiotype antibody mimics the structure of the 
antigen recognized by Ab1.  When Ab2 is injected into the host, the host develops 




Attenuated - weakened or treated in such a way as to decrease the ability of a microorganism 




Attenuated vaccine - a vaccine in which live bacteria or viruses are weakened through chemical 
or physical processes in order to produce an immune response without causing the severe effects 
                                                 
1
 American Heritage Dictionary definition: http://education.yahoo.com/reference/dictionary/entry/adjuvant.  
2
 http://medical-dictionary.thefreedictionary.com/antibody.  
3
 http://medical-dictionary.thefreedictionary.com/humoral+immunity.  
4
 http://medical-dictionary.thefreedictionary.com/antigen.  
5
 http://en.wikipedia.org/wiki/Anti-idiotypic_vaccine.  
6
 http://medical-dictionary.thefreedictionary.com/attenuated+virus.  
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of the disease.  Attenuated vaccines currently licensed in the United States include measles, 
mumps, rubella, polio, typhoid, yellow fever, and chickenpox/shingles.  This is also known as a 
live vaccine. 
 
Attenuation -- defined herein as established by introduction of a heritable genetic alteration or 
gene mutation, or by radiation exposure (preferred), chemical exposure or environmental 
exposure. 
 
B cells – defined herein as small white blood cells that help the body defend itself against 
infection.  These cells are produced in bone marrow and develop into plasma cells that produce 




BLAST – defined herein as the acronym for Basic Local Alignment Search Tool.  This 
program compares nucleotide or protein sequences to sequence databases and calculates the 
statistical significance of matches. 
 
Booster – defined herein as a second or later vaccine dose given after the primary dose(s) to 
increase the immune response to the original vaccine antigen(s).  The vaccine given as the 









DNA (deoxyribonucleic acid) - defined herein as the double-stranded, helical molecular chain 
found within the nucleus of each cell.  DNA carries the genetic information that encodes proteins 




DNA vaccine (nucleic acid vaccine) - defined herein as direct injection of a gene(s) coding for a 
specific antigenic protein(s), resulting in direct production of such antigen(s) within the vaccine 




DWPI – defined herein as Derwent World Patent Index, which is the world’s most 
comprehensive database of patent documents.  DWPI includes over 20 million patent document 
families, which covers over 42.5 million patent documents.  The DWPI database includes 
coverage from over 44 worldwide patent authorities.
12
 
                                                 
7
 http://en.wikipedia.org/wiki/B_cell.  
8
 http://en.wikipedia.org/wiki/Booster_dose.  
9 Crystal Chan, et. al., Advancing Adjuvants and Vaccine Delivery Systems for Better Vaccination Strategies, BioPharm Int’l Supplements, Jan. 2, 
2010. 
10
 http://education.yahoo.com/reference/dictionary/entry/DNA.  
11
 http://www.who.int/biologicals/areas/vaccines/dna/en/index.html.  See also http://www.dnavaccine.com/.  
12




Efficacy - defined herein in vaccine research, the ability of a vaccine to produce a desired 
clinical effect, such as protection against a specific infection or disease, at the optimal dosage 
and schedule in a given population.  A vaccine may be tested for efficacy in Phase 3 clinical 










Epitope - defined herein as a specific site on an antigen that stimulates specific immune 




Expression system - defined herein as in genetic engineering, the cells into which a gene has 




Functional antibody - defined herein as an antibody that binds to an antigen and has an effect 




Gene – defined herein as a unit of genetic material (DNA); a segment of DNA encoding a 




Hemagglutinin (HA) – a major membrane protein of influenza viruses and thus a frequent target 
for immunization strategies to generate protective antibodies.  HA recognizes sialic acid residues 
on the surface of host cells and it functions to attach viral particles to target cells, leading to 
infection of those target cells.
19
  This term is also spelled haemagglutinin. 
 





Immune system - defined herein as the complex system (network of specialized cells and 
organs) in the host body responsible for fighting and responding to disease (immune response). 
Its primary function is to identify foreign substances (antigens of bacteria, viruses, fungi, or 
parasites) in the body and develop a defense against them.  It involves production of proteins 
                                                 
13
 http://en.wikipedia.org/wiki/Vaccine_efficacy.  
14
 http://en.wikipedia.org/wiki/Endemic_%28epidemiology%29.  
15
 http://medical-dictionary.thefreedictionary.com/epitope.  
16
 http://www.news-medical.net/health/Gene-Expression-System.aspx.  
17
 http://en.wikipedia.org/wiki/Antibody.  
18
 http://en.wikipedia.org/wiki/Gene.  
19
 http://en.wikipedia.org/wiki/Hemagglutinin_%28influenza%29.  
20
 http://en.wikipedia.org/wiki/Host_%28biology%29.  
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called antibodies to eliminate these foreign organisms that have invaded the host, and the 




Immunity - defined herein as a natural or acquired resistance provided by the immune system to 
a specific disease. Immunity may be partial or complete, specific or nonspecific, long lasting or 
temporary.  Immunity is indicated by the presence of antibodies and antigen-reactive cells in the 




Immunization - defined herein as the process by which a person or animal becomes protected 
against a disease; the process of inducing immunity by administering an antigen (vaccine) to 
allow the immune system to prevent infection or illness when it subsequently encounters the 




Influenza- herein defined as a virus originating from the family of RNA viruses  
Orthomyxoviridae.  The family Orthomyxoviridae contains three genera, Influenzavirus A, 




INPADOC (International Patent Document Center) – defined herein as a patent database 




ITTI – defined herein as International Technology Transfer Institute, an intellectual 




Neuraminidase (NA) - a major membrane protein of influenza viruses and thus a frequent target 
for immunization strategies to generate protective antibodies.  NA is an enzyme which cleaves 





NCBI – defined herein as the acronym for National Center for Biotechnology 




                                                 
21
 http://en.wikipedia.org/wiki/Immune_system.  
22
 http://medical-dictionary.thefreedictionary.com/immunity.  
23
 http://www.who.int/topics/immunization/en/.  
24
 http://www.niaid.nih.gov/topics/Flu/understandingFlu/Pages/definitionsOverview.aspx.  
25
 http://www.epo.org/searching/essentials/patent-families/inpadoc.html.  
26
 http://law.unh.edu/franklin-pierce-ip-center/international-technology-transfer-institute.  
27
 MJ Sylte and DL Suarez.  2009.  Influenza neuraminidase as a vaccine antigen, Curr. Top. Microbiol. Immunol. 
333:227-4. 
28
 http://www.ncbi.nlm.nih.gov/.  
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Pandemic Influenza - herein defined as a highly pathogenic virus from the family 
Orthomyxoviridae.  The viruses that fall under this category have the capacity to spread rapidly 




Passive immunization – defined herein as the introduction of antibodies or antiserum into a host 
to treat an infection, wherein such treatment does not result in immunological memory and long-




Patent document count – defined herein as an expanded patent family which includes all issued 
patents and patent applications that fall within that family.  
 
Patent family – defined herein as a group of patent documents having a commonality such as 
priority document (INPADOC) or claimed invention (DWPI).  The patent documents can be 
from any jurisdiction. 
 
PCT – defined herein as the Patent Cooperation Treaty, which is an international treaty 
whose goal is to provide a unified procedure for filing patent applications in the contracting 
states.  A contracting state is a country which has signed onto the treaty.  A patent application 





Pharmaceutical Compositions – defined herein as the combination of distinct parts or elements 
to form a whole relating to pharmacy, drugs, or medicine.  This can include anything from 
vitamins, antibodies, antigens, medicaments, and adjuvants. 
 
Seasonal Influenza - herein defined as a virus from the family Orthomyxoviridae that regularly 




Vaccine - defined herein as a preparation that stimulates an immune response that can prevent an 




Veterinary Vaccines- herein defined as vaccines for pandemic influenza for the specific use in 





                                                 
29
 http://www.cdc.gov/flu/pandemic-resources/.  
30
 http://en.wikipedia.org/wiki/Passive_immunity.  
31
 http://www.wipo.int/pct/en/texts/articles/atoc.htm.  
32
 http://www.flu.gov/about_the_flu/seasonal/index.html#.  
33
 http://en.wikipedia.org/wiki/Vaccine.  
34
 http://www.ott.nih.gov/Technologies/abstractDetails.aspx?RefNo=1731.  
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Background of the Technology 
 
Influenza Infections: The Disease 
 
Influenza, more commonly known throughout the world as the flu,
35
 is a highly infectious 
disease caused by the RNA virus family Orthomyxoviridae.  The family Orthomyxoviridae 
consists of three genera of viruses, influenza A, influenza B, and influenza C.  Influenza is 
believed to have originated in birds as this family of viruses has resided in birds for millions of 
years and generally does them no harm.
36
  An influenza-like disease was described as early as 
412 BC by Hippocrates, and the term influenza first appeared in 1357.  The first known influenza 




Influenza viruses frequently mutate and can readily jump the species barrier from wild birds to 
domesticated fowl, such as chickens, ducks or geese, and finally to pigs.
38
  Pigs can be infected 
by both avian influenza and forms of influenza that can infect humans.
39
  In a setting such as a 
farm where chickens, humans, and pigs live in close proximity, pigs can be infected with avian 
and human flu simultaneously and the two types of virus may exchange genes in a process called 
genetic drift.
40
  Such a "reassorted" flu virus can sometimes spread from pigs to people.
41
  It is 
these reassorted viruses that are believed to be the strains that can cause an influenza pandemic.   
 
Nature of an outbreak of a pandemic strain 
As previously mentioned, influenza pandemics occur when a new strain of the influenza virus is 
transmitted from another animal species to human.
42
  These novel strains are unaffected by any 
immunity people may have to older strains of human influenza and can therefore spread 
extremely rapidly and infect very large numbers of people.  Within the past 150 years roughly 
five influenza pandemics have occurred, the 1918 influenza (H1N1) being the earliest and 
deadliest of the pandemics.
43
  Subsequent pandemics were Asian influenza (H2N2) in 1957 and 
Hong Kong influenza (H3N2) in 1968.  The 2009 swine influenza (H1N1) pandemic was the 
most recent.
44
  Because the avian influenza (H5N1, or bird flu), first identified in 1997, was not 




                                                 
35
 The term “flu” is often also used to describe infections by viruses other than influenza, so the more exact term 
“influenza” is used in this report. 
36 http://www.ncbi.nlm.nih.gov/pubmed/7821758.  
37







 http://www.influenzavirusnet.com/history-of-influenza.html.  
44





An example of a pandemic strain of influenza would be the strain more commonly known as the 
1918 Spanish flu.  Given this strain of influenza virus was a novel virus to humans and those 
infected had no previous immunity to this type of virus, the pathology of this disease was 
particularly severe and an estimated 10%-20% of those infected eventually died.
46
  About a third 
of the world’s population was infected and approximately 3%-6% died.47  Given the 
technological advances since the 1920’s, such as increased travel and trade, the globalized 
society we now live in is far more conducive to the rise of another influenza pandemic, as seen 





The Influenza Virus and its Lifecycle  
 
 
Influenza viruses A, B and C are very similar in overall structure. The influenza virus is made of 
a viral envelope containing two main types of glycoproteins, wrapped around a central core.
49
 
The central core contains the viral RNA genome and other viral proteins that package and protect 
the RNA.  The influenza genome is not a single piece; instead, the genome contains seven or 
eight pieces of segmented negative-sense RNA, each piece of RNA containing either one or 
two genes, which code for a protein.
50
  For example, the influenza A genome contains eight 
genes on eight pieces of RNA, encoding for  11 proteins:  hemagglutinin (HA);  neuraminidase  
(NA);  nucleoprotein (NP);  matrix protein (M1);  ion channel protein (M2);  nonstructural 
protein (NS1);  nuclear export protein (NEP, also called NS2);  a polymerase complex composed 




Hemagglutinin (HA) and neuraminidase (NA) are two large glycoproteins found on the outside 
of the viral particles.  HA is a lectin that mediates the binding of the virus to a target cells and 




49 http://www.med.ufl.edu/biochem/bch6415/flu%20lecture%20bfv3.pdf.  
50 University of Florida School of Medicine: http://www.med.ufl.edu/biochem/bch6415/flu%20lecture%20bfv3.pdf.  
51 Id. see also http://www.virology.ws/2009/05/01/influenza-virus-rna-genome/.  
Figure 1.  A rendition of the structure of 
the influenza virus.  Image taken from 
the California Department of Health 
services.  “RNP” denotes 




entry of the viral genome into the target cell.
52
  NA is involved in the release of progeny virus 
from infected cells, by cleaving sugars that bind the mature viral particles.
53
  The HA proteins 
are commonly used as antigens to which antibodies can be raised.
54
 The influenza A viruses are 
classified into subtypes based on antibody responses to HA and NA.  These different types of 
HA and NA form the basis of the H and N distinctions, for example, H5N1.  There are 17 
hemagglutinin and 9 neuraminidase subtypes known, but only H1, H2 and H3, and N1 and N2 





Viruses can replicate only in living cells. Influenza infection and replication is a multi-step 
process.  First, the virus has to bind to and enter the cell, then deliver its genome to a site where 
it can produce new copies of viral proteins and RNA, assemble these components into new viral 
particles, and, last, exit the host cell.
57
 
Influenza viruses bind through hemagglutinin onto sialic acid sugars on the surfaces of epithelial 
cells, typically in the nose, throat, and lungs.
58
  The hemagglutinin is then cleaved by a protease, 





                                                 
52 Id. 
53 http://www.rcsb.org/pdb/101/motm.do?momID=113.  
54 http://www.rcsb.org/pdb/101/motm.do?momID=76.  
55 Id. 
56 http://www.nhs.uk/news/2012/03march/Pages/cdc-finds-h17-bat-influenza.aspx.  
57 http://www.stanford.edu/group/virus/1999/rahul23/replication.html.  
58 http://www.stanford.edu/group/virus/1999/rahul23/replication.html. 
59 http://www.ncbi.nlm.nih.gov/pubmed/20237084. 
Figure 2.  Adapted from  
Neumann et al., 





Once inside the cell, the acidic conditions of the endosome cause two events to occur: first, part 
of the hemagglutinin fuses the viral envelope with the vacuole's membrane, then the M2 ion 
channel allows protons to move through the viral envelope and acidify the core of the virus, 
which causes the core to dissemble and release the viral RNA and core proteins.
60
  The viral 
RNA (vRNA) molecules, accessory proteins and RNA-dependent RNA polymerase are then 
released into the cytoplasm.
61
  
These proteins and vRNA form a complex that is transported into the cell nucleus, where the 
RNA polymerase begins transcribing complementary positive-sense vRNA.
62
  The vRNA can be 
exported into the cytoplasm and be translated or the vRNA can remains in the nucleus.
63
  The 
newly synthesized viral proteins can be either secreted through the Golgi apparatus onto the cell 
surface or transported back into the nucleus to bind vRNA and form new viral genome particles.  
Negative-sense vRNAs that form the genomes of future viruses and other viral proteins are 
assembled into a virion.
64
  Next, molecules of hemagglutinin and neuraminidase cluster into a 
bulge in the cell membrane.  The vRNA and viral core proteins leave the nucleus and enter this 
membrane protrusion.
65
  The mature virus buds off from the cell in a sphere of host phospholipid 
membrane, acquiring hemagglutinin and neuraminidase with this membrane coat.  As before, the 
viruses adhere to the cell through hemagglutinin; the mature viruses detach once 
their neuraminidase has cleaved sialic acid residues from the host cell.
  
After the release of new 





In humans, common symptoms of influenza infection are fever, sore throat, muscle pains, severe 
headache, coughing, and fatigue.
67
  Most people who get influenza will recover in a few days to 
less than two weeks, but some people will develop complications (such as pneumonia) as a result 
of the infection, some of which can be life-threatening.
68
 
Pneumonia, bronchitis, and sinus and ear infections are three examples of complications from 
influenza infections.
69
  Further, influenza can make chronic health problems worse.  For 
example, people with asthma may experience asthma attacks while they are infected with 
influenza, and people with chronic congestive heart failure may have worsening of this condition 




















Influenza virus shedding (the time during which a person might be infectious) begins a day 
before typical symptoms appear; the virus is then released for between 5 to 7 days, although 
some people may shed virus for longer periods.
71
  People who contract influenza are the most 
infective between the second and third days after the initial infection takes place.
72
  The amount 
of virus shed appears to correlate with fever, a higher amount of virus being shed when 
temperatures are higher.
73
   
Influenza is transmitted in three main ways:
 
by direct transmission (when an infected person 
sneezes mucus directly into the eyes, nose or mouth of another person); the airborne route (when 
someone inhales the aerosols produced by an infected person coughing, sneezing or spitting) and 
through hand-to-eye, hand-to-nose, or hand-to-mouth transmission, either from contaminated 
surfaces or from direct personal contact such as a hand-shake.
74
  In the airborne route, the 
droplets that are small enough for people to inhale are between 0.5 to 5 µm in diameter, and 
inhaling just one droplet may be enough to cause an influenza infection.
75  
Although a single 
sneeze can release up to 40,000 droplets,
 
most of these droplets are quite large and will quickly 
settle out of the air.
76
 
As the influenza virus can persist outside of the body, it can also be transmitted by surfaces such 
as banknotes,
 
doorknobs, light switches and other household items contaminated with the virus.
77  
The length of time the virus will persist on a surface varies, with the virus surviving for one to 
two days on hard, non-porous surfaces such as plastic or metal, for about fifteen minutes from 
dry paper tissues, and only five minutes on skin.
78
  However, if the virus is present in mucus, this 
can protect it for longer periods (up to 17 days on banknotes).  Avian influenza viruses can 
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Antigenic Drift and Antigenic Shift 
The composition of the influenza virus can change over time.  This is accomplished through two 
means: antigenic drift and antigenic shift.  Antigenic Drift occurs when small changes in the 
virus (i.e. point mutations in the viral genome) happen continually over time.
80
  These gradual 
changes can produce new virus strains that may not be recognized by the body's immune system.  
A person infected with a particular influenza strain develops antibody against that particular 
virus.  When a new virus strain appears and infects the person, her antibodies which recognize 
the older strains no longer recognize the “new” virus, and re-infection may occur.  This explains 
why people can get influenza repeatedly.  In most years, one or two of the three virus strains in 
the influenza vaccine are updated to keep up with the changes in the circulating influenza 




The other type of change, antigenic shift, is an abrupt, major change in the influenza A viral 
genome, resulting in new hemagglutinin and/or new neuraminidase proteins.
82
  Antigenic shift is 
a recombination event between two viral strains such that a new strain emerges from an animal 
population.  This new strain is so different from subtypes humans have previously seen that most 
people do not have immunity to the new virus.
83
  Such a shift was seen during the spring of 
                                                 
80 http://www.cdc.gov/flu/about/viruses/change.htm.  
81 Id. 
82 http://www.cdc.gov/flu/about/viruses/change.htm.  
83 Id. 
Figure 3.  Courtesy of the 




2009, when a new H1N1 virus with a new combination of genes emerged to infect people and 
quickly spread, causing a pandemic.  While influenza viruses are changing by antigenic drift all 
the time, antigenic shift happens only occasionally.  Type A viruses undergo both kinds of 











Types of Vaccines 
 
Whole virus vaccines - This type of vaccine can be comprised of killed whole viruses or 
attenuated viruses.
85
  Attenuated viruses are live viruses that have been cultivated under 
conditions that disable their virulent properties, or which use closely related but less dangerous 
organisms to produce a broad immune response.
86
  Attenuated virus vaccines typically provoke 
more durable immunological responses and are the preferred type for healthy adults.
87
  
Attenuated vaccines have some advantages and disadvantages.  For example they have the 
capacity of transient growth so they give prolonged protection, and no booster dose is required.  
However, the attenuated virus may revert to the virulent form and cause disease.
88
  Attenuated 





Figures 4A and 4B.  Illustrations 
depicting antigenic drift and 
antigenic shift.  Courtesy of the 
U.S. National Institutes of Health. 
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influenza viruses were traditionally produced in fertilized chicken eggs, but today commercial 
production is more commonly accomplished using mammalian cell cultures (Fig. 5).
89
 
Protein subunit – This type of vaccine is formed by introducing a fragment of microorganism to 
the immune system to create an immune response.
90
  Examples include the subunit vaccine 
against Hepatitis B virus that is composed of only the surface proteins of the virus.
91
  
DNA vaccines – These vaccines use modified. This modified DNA is injected into the cells of 
the body, where the "inner machinery" of the host cells "reads" the DNA and uses it to 
synthesize the pathogen's proteins.
92
  Because these proteins are recognized as foreign, when 
they are processed by the host cells and displayed on their surface, the immune system is alerted, 




                                                 
89





Figure 5.  Production of 




Scope of the Project 
 
The ITTI team began this project after consultation with Dr. Anatole Krattiger, Director of the 
Global Challenges Division at the World Intellectual Property Organization (WIPO).  After the 
discussion, the subject of the project was set to the produce a patent landscape report surveying 
the technologies necessary to produce a vaccine targeted against an outbreak of pandemic 
influenza.  For such a broad subject the ITTI team needed to limit the scope of the project.  The 
ITTI team set the scope of the project to include the following: all types of complete vaccines, 
veterinary vaccines, novel viruses, methods of vaccine production and formulation, methods of 
producing viruses or viral subunits, and general platforms related to influenza vaccines. 
 
The ITTI team decided that complete vaccines are relevant to the subject and thus fall within the 
scope of the project.  Although the ITTI team did not know all of the types of vaccines patents a 
landscape analysis would discover, the ITTI team subdivided the vaccine category into 
whole/attenuated virus vaccines, subtype vaccines, and DNA vaccines.  
 
In reviewing the patents related to vaccines, the ITTI team recognized the need to address the 
issue of when the claims of a patent were directed to vaccines mainly used in animals.  Given 
that a pandemic often involves transmission of virus from animals to humans, and that there is a 
need to vaccinate livestock against influenza, vaccines directed solely to the use in animals were 
included as relevant documents and given a separate category. 
 
Another important decision was whether or not to include vaccines and related technologies only 
covering seasonal influenza.  The issue arose as some seasonal vaccine technologies could be 
potentially adapted to be used to treat pandemic strains of influenza.  The ITTI team decided to 
include technologies that were used for both seasonal and pandemic influenza and for some 
seasonal influenza technologies but not vaccines or antigens restricted solely to seasonal 
influenza.   
 
One of the most important decisions made was how to deal with adjuvants.  The main problem 
with adjuvants is that an adjuvant patent often claims use in vaccines for pandemic influenza in a 
large Markush group, along with hundreds of other diseases.  On the other hand, an adjuvant 
could be limited to just pandemic influenza.  Faced with these two issues, adjuvants were divided 
into two groups, general adjuvants, defined as an adjuvant that listed pandemic influenza in a 
large Markush group, would be excluded from the report
94
 and related adjuvants, defined as 
adjuvants used just for pandemic influenza would be considered relevant.
95
   
                                                 
94
 For example US20090047306A1. 
95
 For example US20110165193A1.  
 25 
 
Patent Search Methodology  
 
Guess, compute the consequences to see what that guess would imply, and 
compare directly with observation to see if it works.  If it disagrees with the 
experiment, it’s wrong.  It’s that simple.  It doesn’t matter how beautiful your 
guess is, how smart you are, or what your name is.  Looking at the universe, the 
great power of science, there’s no such thing as authority of nature.  If it doesn’t 
agree with the experiment, then it’s wrong.  







The iterative process is defined as the act of repeating a process with the aim of approaching a 
desired goal, target, or result.  Each repetition of the process is called an iteration, and the results 
of one iteration are used as the starting point for the next iteration.  In the field of patent 
searching, the iterative process is a searching methodology wherein at the end of a search cycle, 
the search is evaluated, and its shortcoming assessed.  The shortcomings are then addressed in 
the next cycle of searches in order to capture the documents.  The next search can be either wider 
in scope or could be a narrower search depending on the results gained from the previous search.   
 
In this study, keyword searching identified relevant documents, from which were extracted 
further keywords as well as classification codes.  The classification codes were used to locate 
additional documents.  Keywords were adjusted and used for another round of searching. 
 
Figure 6. Iterative 








The number of patent documents worldwide, including patents (issued, re-issued, and re-
examined) and applications, is over 60 million
97
.  Selecting relevant documents from such a huge 
dataset can be difficult, and this type of document retrieval is governed by the mathematical 
theory of Precision and Recall.  Precision is the percentage of retrieved documents that are 
relevant and is calculated as the number of retrieved relevant documents divided by the total 
number of retrieved documents.  Recall is the fraction of relevant documents retrieved and is 
calculated as the number of retrieved relevant documents divided by the total number of existing 
relevant documents.  These concepts are illustrated in Figure 7
98
 below.  
 
Figure 7.  Increasing precision of a search means some relevant results are excluded.  
 
Thus, any set of retrieved of documents will always include a certain fraction of irrelevant 
documents, also termed false positives.  As a search attempts to capture an ever higher fraction 
of relevant documents, the sensitivity of the search will decrease because the proportion of false 
positives will increase.  In the extreme, every relevant document can only be captured if every 
irrelevant document is also captured, as depicted in Figure 8
99
. 
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 See also J. Davis and M. Goadrich, The relationship between precision-recall and ROC curves, Proceedings of the 
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 International Conference on Machine Learning, Pittsburgh, PA, 2006. 
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 Precision Recall Graph, Mirrored ROC Curve, www-csli.stanford.edu.  
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Figure 8.  Inverse relationship between recall and precision.   
 
Stated another way, a high recall means you haven't missed anything but you may have a lot of 
useless results to sift through (which would imply low precision).  High precision means that 
everything returned was a relevant result, but you might not have found all the relevant items 




             
Figure 9.  An optimal balance can be achieved which is neither 100% precise nor 
contains 100% recall. 
 
An optimal balance, point C in Figure 9
101
, must therefore be achieved between precision (degree 
of relevance of all retrieved documents) and recall (fraction of relevant documents retrieved).  In 
terms of patent searching, and in particular searching for relevant vaccine patents within the 
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influenza vaccine landscape, one deciding on that balance point must have experience in patent 
searching in general, knowledge concerning the technology involved, and an understanding of 
the goal of the search.  The purpose of the methodology described in the previous report and 
refined in this update is to provide a framework for such a decision-making process.  
 
A search method example that resulted in high levels of recall and low levels of precision is 
semantic searching.  In this search method, recall was high but precision was low.  The reason 
semantic searching may have been less than effective is that the boundaries that create accuracy 
in a search, the keywords, were computer generated.  Although it is difficult to judge the 
precision levels of semantic searching based on our limited attempts, this results seem to indicate 
that the keywords generated by a computer do not result in high levels of precision.  
 
Other databases were more successful for obtaining high levels of precision.  For example, when 
the search string was controlled and the database being searched was efficient, the results that 
were obtained were an optimal balance between precision and recall.  For example, Derwent is a 
pre-screened database, where language and classifications are carefully standardized.  Therefore, 
precision is increased due to accuracy and efficiency of searching. 
  
Platform Services  
 
U.S. Patent and Trademark Office
102
 
ITTI utilized the USPTO database for classification searching, a patent search platform created 
by the United States Patent and Trademark Office, which provides function to search for patents 
within any of the USPTO’s classifications.  The USPTO database also allows for non-





ITTI utilized Thomson Innovation, a patent search platform that integrates the best of the suite of 
Thomson tools, Aureka, Delphion and MicroPatent.  Thomson Innovation is a single, 
integrated tool that combines intellectual property, scientific literature, business data and 





ITTI also utilized TotalPatent, a LexisNexis platform, to search patents and patent 
applications world-wide.  TotalPatent provides several additional countries that are not 
included in other platforms.  Also, TotalPatent offers useful tools such as semantic searches, 
the ability to search for subsidiary companies and corporate structure, and analytics. 
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 http://www.uspto.gov/.  
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 http://info.thomsoninnovation.com/.  
104





ITTI also performed sequence searching to corroborate the results from conventional search 
methods.  ITTI performed the sequence searches after searching non-patent literature in NCBI’s 
PubMed.
105
  The non-patent literature documents were generally scientific articles containing 
nucleotide and protein sequences related to the relevant technology.  The sequences referenced in 
the articles were inserted into GenomeQuest
106
 and ITTI used the BLAST algorithm
107
 to 
perform a search that produced patents with the same or similar nucleotide or protein sequences.  
 
The sequence searches were performed concurrently with the conventional search methods.  The 
sequence search results were used to corroborate results and also to ensure that ITTI was not 
overlooking any patents within the relevant technology field.  
 
Sequence searching using PubMed and GenomeQuest produces an abundance of non-patent 
literature and provides a way to narrowly search for patents related to the relevant technology. 
Overall sequence searching allowed ITTI to corroborate its results and revealed that ITTI had not 
missed any major portions of the relevant technology.  However, sequence searching produces 
results narrowly confined to those nucleotide or protein sequences and thus becomes a tedious 
search method if used predominantly.  ITTI’s sequence searching method is thus best used as an 
initial search for non-patent literature and also as a way to corroborate search results.  
 
Deduplication Process and Collapsing into Families 
 
The search results from ITTI’s secondary patent searches were combined to form a single list of 
patent documents.  The combined search results were placed into Microsoft Excel as publication 
numbers and deduplicated.  The number of duplicates was taken as an indication of the level of 
recall.  For example, a high percentage of duplicates would mean that most of the relevant results 
had been identified.  However, publications numbers with different file extensions, such as PCT 
extensions A1, A2, and A3, would be recognized as different even though the numbers 
corresponded to the same application.   
 
A further method of deduplication employed Thompson Innovation.  A publication number 
search was performed and all related INPADOC family members were returned in the result set.  
The data was saved as a work file.  The same procedure was performed with a different team 
member’s search results.  One work file could be subtracted from the other, and the size of the 
subtracted file would indicate the level of overlap and thus the level of recall being achieved.  
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 http://www.ncbi.nlm.nih.gov/pubmed/.  
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 http://www.genomequest.com/.  
107
 http://blast.ncbi.nlm.nih.gov/Blast.cgi.  
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The work files could also be merged, and Innovation would automatically remove duplicates in 
the merged work file. 
 
Once a compiled list of all search results was deduplicated, the results were then collapsed by 
INPADOC family to reduce the initial search results into representative patent family 
documents.  ITTI gave preference to US documents because these documents were easier for the 
team to analyze and they tended to contain the most complete bibliographic information 
available.  The collapsed list was a much more manageable number of documents which the 
team could efficiently code into categories.  The team recognizes that the representative family 
member could be a divisional application and thus would not claim the full limit of the invention.  
Although this could result in an error, either towards inclusion or exclusion, time constraints 










A master of list of influenza-related documents was assembled following three complete rounds 
of searching by each of the four team members.
108
  On the second round of searching, about 25% 
of over 15,000 documents were repeated among the different members’ results.  However, the 
third round of searching generated only 78 new INPADOC families, compared to over 3,700 
previously identified families, which was only a 2% increase in the results.  Thus, the team was 
confident that at least 98% of the influenza-related documents had been captured.   
 
The results were compiled and a publication number search was performed using Innovation to 
expand the families.  Approximately 33,500 total documents were identified, and these results 
were collapsed into almost 3,800 INPADOC patent families.
109
  Representative family members 
were then subjected to a coding process.  Publications that were irrelevant to influenza or were 
outside the scope of this project were excluded.  Documents were also excluded if they were 
duplicates (such as an application and a patent that was issued from that application which was 
not assigned properly to the same INPADOC family
110
), or if there was too little information in 




Documents were considered relevant if they specifically claimed influenza or members of the 
orthomyxovirus family.  Coding was done on the claims of the representative family members, 
or, if no claims were available, coding was done using other family members.  INPADOC family 
members were given preference, but DWPI family members were used alternatively.  Family 
members were selected in the following order, as available: a U.S. application (assumed to have 
the broadest claims), U.S. patent, a PCT application, and finally a document having claims in 
English, such as a document from Great Britain or Australia.  If no family members had claims 
in English, foreign language claims were translated into English using Google Translate.
112
  If 
there were no family members having claims in their records, the family was coded using a 
DWPI summary of the claims, or if absolutely necessary, on the abstract alone.  In the final case, 
the coding was done very conservatively and the document was excluded unless it obviously 
related to a prophylactic influenza A vaccine.   
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 The keywords used in patent searching are located in Appendix L. 
109
 Results are given in approximations because new family members were continually being identified and 
publications were added to existing families.  Thus, the actual numbers changed each week with total documents 
increasing and the number of families decreasing. 
110
 For example, IE6500388A is the application for issued patent IE28884L, but the documents were not assigned to 
the same INPADOC family. 
111
 For example, IT1379280B. 
112
 http://translate.google.com/.  
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In this manner, over 97% of the results were either assigned to one of the coding categories given 
below or were excluded as outside the scope of this report.  Many documents were relevant to 
multiple categories, but each representative family was placed in only one category, that 
category being the best fit for the overall focus of the document.  For example, a document 
claiming both a complete vaccine and the components to be assembled into that vaccine was 
placed into one of the vaccine categories.  Alternatively, if the document focused on the process 
of making the vaccine, the document was coded to one of the method categories.  In general, 
there were four major categories for coding documents: vaccines, supporting technologies, 
general platforms, and excluded documents.  The first two categories were divided into 
subcategories.  The definitions and criteria for each category are given below.  The Master 
Coding Document can be found in Appendix A. 
 
 
Coding Categorization of Patent Documents 
 
General platforms.  
A document had to specifically claim influenza in order to be considered relevant.  However, 
about 15% of the results claimed influenza only generally, such as in a large Markush group
113
 or 
only in one dependent claim
114
.  The technology described in such documents could be useful in 
constructing an influenza vaccine, but could just as easily serve as a platform for vaccines 
against a wide range of pathogens.  These documents were considered to have a low level of 
relevance.  While these documents are captured and reported in Appendix B, they are not 
included in any of the analysis below. 
 
Vaccines. 
Vaccines were divided into three subcategories: whole virus vaccines, subunit vaccines, and 
DNA vaccines.  Whole virus vaccines included live, attenuated (live but avirulent), or killed 
whole virus particles.  This group would also contain split (digested) but unfractionated 
preparations of viruses, so that the vaccine contained all possible influenza antigens.  Many of 
these whole viruses were recombinant virions which contained one or more antigens from a 
pandemic virus expressed by an otherwise nonpathogenic virus.   
 
 Subunit vaccines contain individual influenza antigens or a mixture of a limited number 
of antigens, but less than a complete virus.  The antigens could either be purified from whole 
viruses or produced as recombinant versions of the native protein.  The subunits could be also be 
expressed by non-influenza viruses that act as a carrier for the influenza antigen or as a 
secondary source of antigens to create a multivalent vaccine, such as a recombinant vaccinia 
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 For example US6207171B1. 
114
 For example US20110111017A1. 
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virus carrying an influenza H5 antigen.
115
  The influenza antigens could also be expressed by 
bacteria such as salmonella
116




 DNA vaccines are nucleic acid constructs which, when injected into an animal, cause 
expression of an influenza antigen by host cells that take up the nucleic acid constructs.  DNA 
vaccines are typically very good at stimulated cell-mediated immunity, such as cytotoxic T 
lymphocytes which would in turn destroy influenza-infected host cells.  These nucleic acid 
constructs could be either linear pieces of DNA or RNA, which are short-lived in the host, or 
DNA plasmids, which can persist for a period of time. 
 
 To be considered a vaccine-related publication, the representative document must have 
claimed compositions of matter having all aspects of a true vaccine: antigen(s), adjuvant (if 
necessary), carriers/diluents, and a means or route of delivery.  If the claims do not meet these 
aspects, or were solely method claims, the family was placed in one of the supporting technology 
categories.  Merely terming a composition was not sufficient; the claims must have had enough 
detail to describe an actual vaccine.  Some allowance was made for foreign language documents 
in that a broader range of terminology was accepted as a description of a vaccine.  Vaccine 
documents are reported in Appendix C. 
 
Supporting Technologies. 
Some documents claimed influenza in independent claims yet did not sufficiently claim a 
vaccine composition for use in humans.  These documents were coded as one of the supporting 
technologies which are important for the construction or manufacture of vaccines.  Included in 
the supporting technologies subcategories are novel viruses useful in vaccines and novel subunit 
constructs useful in vaccines.  These documents describe the antigenic components of a vaccine, 
but lack detail of carriers, adjuvants, and route of administration.  Thus these two subcategories 
were focused on compositions of matter. 
 
Two other subcategories of the supporting technologies were focused more on methods utilized 
in vaccine manufacture.  The first such subcategory contains documents describing methods of 
making vaccines, which includes procedures for purifying antigens
118
 and for formulating 
vaccines, such as the addition of a specific adjuvant
119
 or preparations for intranasal delivery.
120
  
The other subcategory was established for documents which disclosed methods of producing 
virus or viral subunits.  These method including nucleic acid constructs which could be used to 
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 cell lines which could be used to produce viruses,
122
 or nucleic 
acid constructs encoding recombinant versions of influenza antigens.
123
  While the former 
subcategory was mostly for method patent documents, the latter subcategory contained a mixture 
of method and composition of matter claims. 
 
A final subcategory under the heading of supporting technologies was for veterinary vaccines.  
While the documents in this subcategory described complete vaccines, those vaccines were not 
for use in humans, although it is possible some may have been able to be adapted for human use.  
These vaccines were for birds (mostly chickens), pigs, horses, dogs, and other domesticated 
animals.  Such vaccines may be useful not only veterinary purposes but also to prevent 
transmission of novel influenza strains to humans. 
 
The heading of supporting technologies thus contains a broad spectrum of patent documents 
covering a variety of different technologies.  However, all of these documents are relevant to the 
production of influenza vaccines and the prophylactic treatment of human populations.  The 
entire list of these documents is presented in Appendix D.  
 
Note on the order of placement  
As mentioned above, representative documents may have fit in multiple categories, but the 
documents were placed in the category which was the most relevant to the overall focus of the 
document.  The order of placement was: 
1. Whole virus vaccines 
2. Subunit vaccines 
3. DNA vaccines 
4. Methods of making vaccines 
5. Methods of producing virus or viral subunits 
6. Veterinary vaccines 
Documents were placed in the highest category in which the claims from that document fit.  
However, if no claims were available in the record of that document or any of its family 
members, the document were conservatively coded, mostly in the lower categories.  If the 
available record mentioned multiple pathogens, the document without claims was often placed in 
the platform category. 
 
Excluded irrelevant documents 
Approximately half of the documents were excluded as irrelevant or as having insufficient 
information to allow coding.  The full list of these documents can be found on the Master Coding 
Sheet in Appendix A, but it is useful to detail the reasons for exclusions here, to clarify the scope 
of the project. 
                                                 
121
 For example US7723094B2.  
122
 For example US20100233674A1.  
123




1. Therapeutic interventions, such as small molecule medicines which inhibit viral 
replication or function.  Therapeutics also include interfering RNA (RNAi) molecules. 
2. Means of detecting the presence of influenza virus. 
3. Diagnostic methods. 
4. Passive immunization. 
5. Antibodies directed against influenza.  These could be used in any of the above 
categories.  A few patent document mentioned using anti-influenza antibodies to 
stimulate anti-idiotype responses, but none of those documents disclosed an anti-idiotype 
monoclonal antibody that could be used to immunize humans. 
6. Adjuvants, when influenza is not specifically claimed. 
7. Devices, such as surgical masks to prevent infection. 
8. Delivery systems for vaccines. 
9. Immunization schedules, when a particular vaccine formulation is not disclosed. 
10. Herbal medicines, which were common among Chinese documents. 
11. Documents actually related to Haemophilus influenzae, a bacteria often present in lung 
infections.  Searches for the influenza virus often returned this pathogen as well. 
12. Documents actually related to parainfluenza, a distantly-related virus in the 
paramyxovirus family.  Searches for the influenza virus often returned this pathogen as 
well. 
13. Documents in which influenza is used only as a tool, such as a fusion partner for other 
antigens or as immunostimulatory peptides employed as adjuvants.  Sometimes 
recombinant influenza viruses were constructed to contain antigens for other pathogens.  
While these documents did relate to anti-influenza immune responses, they are not 
relevant to the generation of prophylactic immunity against pandemic influenza. 
14. Documents related to seasonal influenza only, such as influenza B. 
15. Quality control methods for standardizing vaccines.  The team decided such documents 
were too peripheral to vaccine production. 
16. Sterilizing methods or devices.  This includes removal of viruses from blood products 
prior to transfusion, for example. 
17. Computer programs used to predict antigenic epitopes, unless such epitopes were 
specifically identified and claimed. 
18. Dietary supplements which supposedly boosted immunity or otherwise prevented 
infections. 
19. Documents in which influenza was not claimed.  Particularly in some general platform 
technologies, influenza may be mentioned in the abstract but not in the claims. 
20. Documents which were not related to influenza. 
 
The last reason needs to be expanded upon, as a small percentage of the results had no relation to 
influenza but the presence of such documents in a result set is always a concern.  In some cases, 
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influenza peptides were used in assays which were summarized in the Derwent abstract, but the 
document was not focused on influenza.  Other documents did not relate to the vaccine field in 
any way.  These documents may have been returned because some jurisdictions re-use patent 
numbers with different file extensions, and TotalPatent mistakenly considers the two documents 
to be family members.  For example, CN1147316C is a patent disclosing a subunit vaccine and is 
a family member with US5948410A, but CN1147316A is a patent for bricks used in walls and 
floors.  Other countries, such as Japan, also have confusingly similar patent numbers to describe 
unrelated technologies. 
 
Distribution of coding categories 
The relative distribution of the results into the various categories is given in Table I.  One-third 
of the results were considered relevant as either a vaccine document or a document describing 
one of the supporting technologies.  Analytics was performed on these patent documents.  The 
remainder of the results are reported in the appendix but were not included in the analysis. 
 
Table I. Distribution of results (3,800 families) into coding categories. 
Vaccines 15.0% 
           Whole virus vaccines  (6.5%) 
           Subunit vaccines  (6.7%) 
           DNA vaccines  (1.9%) 
Supporting Technologies 19.8% 
          Novel viruses useful in vaccines  (2.3%) 
          Novel subunits useful in vaccines  (2.7%) 
          Method of making vaccines  (6.7%) 
          Method of producing virus or viral subunits  (4.5%) 
          Veterinary vaccines  (3.7%) 
Platform technologies 14.7% 
Excluded due to lack of information or as duplicates  2.3% 
Excluded as irrelevant 48.2% 
 
Pandemic Influenza Documents 
 
Searching was done for influenza-related patent documents which were then categorized based 
on their relationship to vaccines for influenza A.  Not all documents were specific as to whether 
the technology could be used with pandemic influenza strains, seasonal influenza strains, or both.  
The team decided to err on the side of inclusion, so that a document was considered relevant if it 
mentioned influenza generally, pandemic influenza strains, or both pandemic and seasonal 
strains.  Only if the document was specifically limited to seasonal influenza was it excluded.  
Approximately 20% of families in the vaccine category and 10% of families in the supporting 
technology category referenced either pandemic or epidemic influenza in the DWPI title or 
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abstract.  Documents representing each family are presenting in Table II.  Full information on 
those documents can be found in Appendices C and D. 
 
Table II.  Documents representing a patent family referencing pandemic influenza. 
Publication 
Number 
Title - DWPI Assignee/Applicant 
Vaccine Category 
  AU2012216357A1 New recombinant adenovirus vector comprises a 
polynucleotide encoding at least one antigen of 
an avian influenza strain, useful for producing 
vaccines for eliciting an immune response 
against avian or pandemic influenza 
PURDUE RESEARCH 
FOUNDATION | GOVERNMENT 
OF THE US SECRETARY OF THE 
DEPT OF HEALTH AND HUMAN 
SERVICES CT S FOR DISEASE 
CONTROL AND 
CN101053658A Preparing composite multi-epitope bivalent 
nucleic acid vaccine for preventing H3,H9 
subtype influenza virus, by obtaining a 
composite multi-epitope target Epi gene, and 
inserting into pIRES1neo expression vector 
JIN Ning-yi,Changchun, Jilin 
130062,CN 
CN101450209B New transdermal influenza immunization 
multivalent vaccine comprising transdermal 
agent, transdermal immune adjuvant, and 
influenza multivalent vaccine antigen, useful for 
immunizing Balb/c mouse, ferret, monkey, and 
humans 
Academy of Military Medical 
Sciences of The CPLA Institute of 
Microbiology and 
Epidemiology,CN 
CN101524538A New influenza-pandemic influenza bivalent 
combined vaccine comprises influenza 
immunogen, pandemic influenza immunogen, 
and vaccine adjuvant, for treating or preventing 
influenza, pandemic influenza, or bird flu viral 
epidemic influenza 
Chengdu Kanghua Biological 
Products Co. Ltd.,Chengdu, 
Sichuan 610100,CN 
CN101745109A Influenza virus vaccine preparation involves 
inoculating Influenza A and B influenza viruses 
into allantoid cavity of ten days old thousand 
healthy chick embryos to amplify influenza 
viruses 
Yunnan Valvax Biotechnology 
Co. Ltd.,Kunming, Yunnan 
650106,CN 
CN101808659A Inactivated influenza vaccine comprises beta 
propiolactone inactivated whole influenza virus 
and a mono- or disaccharide derivative having 
specific fatty acid ester groups, as an adjuvant 
NOBILON INTERNAT B V,NL 
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CN101816785B Preparing H9N2 subtype avian influenza 
inactivated vaccine comprises screening, 
identifying, and domesticating virus in a cell line, 
and initial amplification culturing the virus in the 
cell 
Yangzhou Youbang 
Biopharmaceutical Co. Ltd.,CN 
CN101879312B New M2e-carrier protein coupler, chemically 
coupled by ectodomain M2e of influenza A 
H1N1 virus M2 protein, useful for preventing 
influenza 
Beijing Jingyi Technology 
Development Co. Ltd.,CN 
CN101926994B Immunoadjuvant used in influenza vaccine, 
comprises turtle shell extract and carrier, and 
has low side effect and is prepared in simple, 
cost-effective and eco-friendly manner 
Institute of Medical Biology 
Chinese Academy of Medical 
Sciences,CN | Chinese Academy 
of Sciences Kunming Institute of 
Botany,CN 
CN101926995A Immunoadjuvant used in influenza vaccine, 
comprises Asparagus extract and carrier, and is 
safe and prepared in simple, cost-effective and 
eco-friendly manner 
Chinese Academy of Sciences 
Kunming Institute of Botany,CN 
| Institute of Medical Biology 
Chinese Academy of Medical 
Sciences 
CN102068692A Influenza virus split vaccine comprises influenza 
virus hemagglutinin (H1N1), H3N2 and B types, 
CpG oligodeoxynucleotides adjuvant and 
aluminum adjuvant 
Beijing Minhai Biotechnology 
Co. Ltd.,CN 
CN102397559A New HA218-72-carrier protein conjugate useful 
for preventing or treating influenza 
Beijing Jingyi Technology 
Development Co. Ltd.,CN 
CN1810961B Recombinant influenza virus useful as vaccine, 
involves inserting PB2, PB1, PA, M, NS and NP 
coding genes from cold-adapted strain of type-A 
or type-B influenza virus into eukaryotic cell 
expression plasmid 
INST MICROBIOLOGY & 
EPIDEMIOLOGY 
EP1599581A2 New attenuated influenza virus, useful as 
vaccine, has altered protease cleavage site in 
hemagglutinin, is not pathogenic but still 
immunogenic 
Transmit Gesellschaft für 
Technologietransfer mbH,35394 
Giessen,DE,03201700 | Philipps 
Universität Marburg,35032 
Marburg,DE,04124880 
FR2866031B1 Viral chimer, useful to e.g. treat viral diseases, 
comprises capsid and/or lipidic envelop, 
defective genome, genome to serve a helper 
virus and genome comprising nucleotide 
sequences encoding polypeptides used in viral 
antigenicity 




HK1144374A0 Preparing an influenza vaccine from influenza 
virus grown in a culture of a mammalian cell line 
by testing the vaccine or culture for an infectious 
agent that can grow in the cell line but that does 
not grow in embryonated hen eggs 
 
HK1144904A0 Eliciting or inducing a protective immune 
response in a subject against a pandemic 
subtype of influenza virus, comprises 
administering to the subject a composition 
comprising an immunogen of an endemic 
influenza subtype 
 
HK1146807A0 New monovalent influenza vaccine, useful 
particularly for preventing infection by pandemic 
strains, contains low dose of egg-derived antigen 
 
HK1155639A0 Kit for raising immune response in patient for 
protecting against influenza virus infection 
comprises aqueous inactivated influenza vaccine 
 
IN200703448P2 Immunogenic composition for preparing 
vaccines against e.g. influenza virus comprises 
influenza antigen from at least two influenza 
virus strains and at least one strain associated 
with pandemic outbreak and oil-in-water 
emulsion adjuvant 
 
IN200703777P4 New nucleic acid construct, comprises chimeric 
promoter sequence, coding sequence, non-
translated leader sequence, and enhancer 
sequence, for inducing an immune response 
against influenza virus hemagglutinin (HA) 
antigen 
 
IN200704067P2 Use of an influenza virus or antigenic 
preparation, and an oil-in-water emulsion 
adjuvant, for inducing at least one of an 
improved CD4 T-cell immune response, and an 





IN200704150P2 New recombinant adenovirus vector comprises a 
polynucleotide encoding at least one antigen of 
an avian influenza strain, useful for producing 
vaccines for eliciting an immune response 
against avian or pandemic influenza 
 
IN200801841P2 New immunogenic composition comprising an 
influenza virus antigen, an oil-in-water emulsion 
adjuvant and a cytokine-inducing agent, useful in 
raising an immune response against influenza 
virus infection in a patient 
 
IN200801873P2 New immunogenic composition comprises split 
influenza virus antigen and oil-in-water 
emulsion, where the emulsion includes free 
surfactant in its aqueous phase, useful as 
vaccine for protecting against influenza virus 
infection 
 
IN200805247P2 New monovalent influenza vaccine composition 
comprises low amount of influenza virus antigen 
from an influenza virus strain that is associated 
with a pandemic, useful for protecting a human 
from influenza infection 
 
IN200903238P2 New immunogenic influenza composition, 
comprises an influenza virus antigen or antigenic 
preparation in combination with an oil-in-water 
emulsion adjuvant, useful for treating or 
preventing diseases caused by influenza 
infection 
 
IN201001237P2 Eliciting or inducing a protective immune 
response in a subject against a pandemic 
subtype of influenza virus, comprises 
administering to the subject a composition 
comprising an immunogen of an endemic 
influenza subtype 
 
IN201001619P4 Inactivated influenza vaccine comprises beta 
propiolactone inactivated whole influenza virus 
and a mono- or disaccharide derivative having 




IN201004612P2 Kit for raising immune response in patient for 
protecting against influenza virus infection 
comprises aqueous inactivated influenza vaccine 
 
IN201100348P4 Immunogenic composition, useful for treating 
influenza, comprises types A and B influenza 
hemagglutinin proteins 
 
JP04031478B2 Recombinant influenza haemagglutinin 
produced in baculovirus system avoids problems 
of growing virus in eggs and produces stable, un-
cleaved protein useful in vaccines 
PROTEIN SCI,JP 
JP2009102416A Recombinant influenza haemagglutinin 
produced in baculovirus system avoids problems 
of growing virus in eggs and produces stable, un-
cleaved protein useful in vaccines 
PROTEIN SCIENCES 
JP2011519828A New flagellin amino acid sequences for treating 
e.g. influenza virus infection comprises specific 
deletion and replacement constructs having 
sequence identity to specific flagellin sequences, 
where sequences activate toll-like receptor-5 
 
KR1999022028A Recombinant influenza haemagglutinin 
produced in baculovirus system avoids problems 
of growing virus in eggs and produces stable, un-
cleaved protein useful in vaccines 
 
KR2010045436A New isolated attenuated influenza virus strain 
comprises internal genome segments of 
A/PR/8/34(H1N1) and surface antigens 
hemagglutinin and neuraminidase of 
A/Aichi/2/68(H3N2), useful as vaccines against 
influenza virus infections 
BIOTRION INC. 
MX290169B Use of an influenza virus or antigenic 
preparation, and an oil-in-water emulsion 
adjuvant, for inducing at least one of an 
improved CD4 T-cell immune response, and an 





MX293233B Stabilizing influenza vaccine composition 
comprises diluting liquid bulk composition, 
subjecting regular droplets to freezing to form 
frozen regular spherical micropellets or particles, 
and drying 
 
PH12009500128A New monovalent influenza vaccine composition 
comprises low amount of influenza virus antigen 
from an influenza virus strain that is associated 
with a pandemic, useful for protecting a human 
from influenza infection 
 
RU2077581C1 New vaccine strain A (47) Texas-91(2)6 (H1N1) 
can be used in medicinal virology, for production 
of live influenza vaccine for children 
NIIEX MEDITSINY RAMN 
RU2077582C1 New vaccine strain A (17) Shangdong (93) 3/5 
(H3N2) can be used in medicinal virology, for 
production of live influenza vaccine for adults 
NIIEX MEDITSINY RAMN 
RU2099086C1 Prevention of influenza epidemics in children by 
intranasal administration of live attenuated cold 
adapted vaccine 
NIIEX MEDITSINY RAMN 
RU2110277C1 New strain A(17) of influenza virus Johannesburg 
(94) 1 (H3 N2) GISK N 391 used for production of 
live intranasal influenza vaccine for adults 
NI SKIJ I EHKSPERIMENTAL | NOJ 
MEDITSINY RAMN 
RU2110278C1 New strain A(17) of influenza virus Johannesburg 
(94) 1 (H3 N2) GISK N 392 used for production of 
live intranasal influenza vaccine for children 
NOJ MEDITSINY RAMN | NI SKIJ 
I EHKSPERIMENTAL 
RU2127757C1 Strain a/47/nanchang/95/13 (h3n2) for 
production of live antiinfluenza intranasal 
vaccine for children 
NOJ MEDITSINY RAMN | NI SKIJ 
I EHKSPERIMENTAL 
RU2128223C1 Strain a/17/nanchang/95/4 (h3n2) for 
production of living an antiinfluenza intranasal 
vaccine for adults 
NOJ MEDITSINY RAMN | NI SKIJ 
I EHKSPERIMENTAL 
RU2144955C1 Strain of influenza virus a/17/pert/95/29(H1N1) 
for production of live anti-influenza intranasal 
vaccine for adult humans 
NII EHKSPERIMENTAL | NOJ 
MEDITSINY RAMN 
RU2159809C1 Influenza virus strain a/47/sydney/97/14 (h3n2) 
for production of live influenza intranasal 
vaccine for babies 




RU2159810C1 Influenza virus strain a/47/peking/95/35 for the 
production of live influenza intranasal vaccine 
for babies 
NII EHKSPERIMENTAL NOJ 
MEDITSI 
RU2159811C1 Influenza virus strain a/17/peking/95/25 (h1n1) 
for production of live influenzal intranasal 
vaccine for adults 
NII EHKSPERIMENTAL | NOJ 
MEDITSINY RAMN 
RU2183672C1 A novel strain of influenza virus A/17/New 
Caledonia/99/145 (H1N1) for production of live 
anti-influenza, intranasal vaccine for adults 
NII EHKSPERIMENTAL | NOJ 
MEDITSINY RAMN 
RU2185437C1 Strain of influenza virus a/47/new 
caledonia/99/156 (H1N1), useful for production 
of live influenza intranasal vaccine for children 
NII EHKSPERIMENTAL | NOJ 
MEDITSINY RAMN 
RU2248394C1 New influenza virus strain A/47/panama/99/234 
(H3N2) for producing a live anti-influenza 
intranasal vaccine for children 
 
RU2248395C1 New strain A/17/Panama/99/242 (H3N2) for 
producing a live anti-influenza intranasal vaccine 
for adults 
 
RU2266329C1 Strain for production of living influenza 
intranasal vaccine for adults and infants 
 
RU2315101C2 Vaccine strain of influenza virus 
a/17/california/04/6 (h3n2) and attenuation 
donor a/leningrad/134/17/k7/57 (h2n2) for its 
preparing 
 
RU2319744C2 Strain of influenza virus, gisk 147, used for 
preparing influenza intranasal vaccine for adults 
and children 
GU NII EHKSPERIMENTAL NOJ 
MEDI 
RU2416640C1 Vaccine strain of a/17/brisbane/07/1 (h3n2) 
influenza virus for preparing live influenza 
intranasal vaccine for adults and children 
UCHREZHDENIE ROSSIJSKOJ 
AKADEMII MED NAUK NII 
EHKSPERIMENTAL NOJ 
MEDITSINY SEV ZAP OTDEL 
RAMN NIIEHM 
RU2416641C1 Vaccine strain of a/17/brisbane/07/28 (h1n1) 
influenza virus for preparing live influenza 
intranasal vaccine for adults and children 
UCHREZHDENIE ROSSIJSKOJ 
AKADEMII MED NAUK NII 
EHKSPERIMENTAL NOJ 




RU2422518C1 Vaccine strain of a/17/solomon islands/06/9 
(h1n1) influenza virus for preparing live 
influenza intranasal vaccine for adults and 
children 
UCHREZHDENIE ROSSIJSKOJ 
AKADEMII MED NAUK NII 
EHKSPERIMENTAL NOJ 
MEDITSINY SEV ZAP OTDEL 
RAMN NIIEHM 
RU2422519C1 Vaccine strain of b/60/florida/04/181 influenza 
virus for preparing live influenza intranasal 
vaccine for adults and children 
UCHREZHDENIE ROSSIJSKOJ 
AKADEMII MED NAUK NII 
EHKSPERIMENTAL NOJ 
MEDITSINY SEV ZAP OTDEL 
RAMN NIIEHM 
SU1571067A1 Influenza virus strain used in prepn. of living 
influenza vaccine for children and adults 
VNII GRIPPA | LE NII VAKTSIN 
SYVOROTOK | GNII 
STANDARTIZAT KONTROL 
SU1655985A1 Live intranasal vaccine against influenza gp. A 
virus for children involves using specified 
recombinant strain of virus to increase efficiency 
NIIEX MEDITSINY AMN SSSR | 
MO NII VIRUSNYKH 
PREPARATOV | VNII GRIPPA | 
GNII STANDARTIZAT KONTROL 
TW200628611A New nucleic acid construct, comprises chimeric 
promoter sequence, coding sequence, non-
translated leader sequence, and enhancer 
sequence, for inducing an immune response 
against influenza virus hemagglutinin (HA) 
antigen 
 
TW200700078A Immunogenic composition for preparing 
vaccines against e.g. influenza virus comprises 
influenza antigen from at least two influenza 
virus strains and at least one strain associated 
with pandemic outbreak and oil-in-water 
emulsion adjuvant 
 
TW200700079A Immunogenic composition for preparing 
vaccines against e.g. influenza virus comprises 
influenza antigen from at least two influenza 
virus strains and at least one strain associated 
with pandemic outbreak and oil-in-water 
emulsion adjuvant 
 
TW200722101A Immunogenic composition for preparing 
vaccines against e.g. influenza virus comprises 
influenza antigen from at least two influenza 
virus strains and at least one strain associated 





US20060121447A1 New subfragment of an RNA sequence coding 
for a neuroaminidase protein NAy, useful in 
preparing a vaccine against avian influenza virus 
infection with specific epidemic strain HxNy 
 
US20080254065A1 Vaccine for protecting a human patient against 
infection by a human influenza virus strain, 
comprises an antigen from an avian influenza 




US20100008952A1 Novel replication-defective adenoviral vector 
comprising nucleic acid encoding influenza A 
polypeptide, useful for inducing immune 
response in subject, and as vaccine to reduce 
risk of infection by influenza 
 
US20100099745A1 Inhibiting viral infection in a subject by 
administering recombinant adenovirus vector 
comprising a nucleic acid encoding a caspase 
recruitment domain from melanoma 
differentiation-associated gene 5 or retinoic acid 
inducible gene I 
 
US20100129399A1 New linear expression construct that is free of 
any amplification and/or selection sequences, 
useful for preparing a composition for treating 
or preventing infectious diseases, e.g., avian 
influenza virus infection 
AVIR Green Hills Biotechnology 
Research Development Trade 
AG,Wien,AT 
US20100166769A1 Preparing influenza virus-like particle used as 
vaccine, by inserting recombinant DNA with 
influenza hemagglutinin and neuraminidase 
sequences into Vero cell with influenza M1 and 
M2 sequences and culturing obtained 
coexpression cell 
Academia Sinica,Taipei,TW 
US20100189745A1 Reassortant influenza virus useful as vaccine for 
eliciting immune response comprises internal 
gene segment derived from first influenza virus 
A subtype, and hemagglutinin and 
neuraminidase genes from the influenza virus 
subtype 
BAXTER INTERNATIONAL 





US20100221349A1 New nucleic acid construct, comprises chimeric 
promoter sequence, coding sequence, non-
translated leader sequence, and enhancer 
sequence, for inducing an immune response 
against influenza virus hemagglutinin (HA) 
antigen 
Powderject Vaccines Inc. | 
Powdermed Limited 
US20100291146A1 Eliciting or inducing a protective immune 
response in a subject against a pandemic 
subtype of influenza virus, comprises 
administering to the subject a composition 
comprising an immunogen of an endemic 
influenza subtype 
CSL Limited,Victoria,AU 
US20110097418A1 Immunogenic composition, useful for treating 




US20110129497A1 Manufacturing a composition comprising 
directed-sequence polymers (DSPs) comprises 
selecting an amino acid sequence of an epitope 
of an antigen associated with a disease, and 
synthesizing a cassette of the DSPs 
Peptimmune 
Inc.,Cambridge,MA,US 
US20110150912A1 New live attenuated avian influenza virus useful 
in vaccine for preventing epidemic and 
pandemic influenza, comprises basic 2 protein 
gene and basic 1 protein gene 
 
US20110180430A1 New immunogenic composition comprising an 
influenza virus antigen, an oil-in-water emulsion 
adjuvant and a cytokine-inducing agent, useful in 
raising an immune response against influenza 
virus infection in a patient 
NOVARTIS VACCINES AND 
DIAGNOSTICS SRL,Siena,IT,IT 
US20110229518A1 Use of nucleotides encoding influenza proteins 
e.g. haemagglutinin with few or no glycosylation 
sites for manufacturing immunogenic 
composition or vaccine component against 
present day and coming influenza A infections in 
humans and pigs 
Statens Serum 
Institut,Copenhagen S,DK 
US20110262481A1 New reassortant influenza-A virus comprising 
gene segments of seasonal or pandemic strain 
origin, a polymerase basic protein-1 gene 
segment, and a polymerase gene segment, 
useful e.g. as vaccine to prevent influenza virus 
infection 






US20110287054A1 Immunogenic composition for preparing 
vaccines against e.g. influenza virus comprises 
influenza antigen from at least two influenza 
virus strains and at least one strain associated 
with pandemic outbreak and oil-in-water 
emulsion adjuvant 
GlaxoSmithKline Biologicals s.a. 
US20110305748A1 Composition for immunizing subject against pre-
pandemic influenza virus comprises recombinant 
hemagglutinin from pre-pandemic influenza 
virus, and adjuvant comprising disaccharide 




US20120009215A1 New hemagglutinin and/or neuraminidase 
variant, useful for stimulating an immune 
response against influenza virus, or for 
prophylactic or therapeutic treatment of a viral 
infection 
 
US20120034264A1 New 6:2 reassortment influenza virus, useful as 
a vaccine for stimulating the immune system of 
an individual or for treating or preventing a viral 
infection in a subject 
MedImmune 
LLC,Gaithersburg,MD,US 
US20120064110A1 Dosage form, useful e.g. for the prophylaxis of 
influenza virus infection, preferably influenza A 
virus infection, comprises synthetic nanocarriers 
coupled to peptides that are obtained from 
human influenza A virus hemagglutinin 
Selecta Biosciences 
Inc.,Watertown,MA,US 
US20120064115A1 Recombinant virus-like particle used as vaccine 
comprises at least two different 
epitopes/proteins containing epitopes selected 
from different viral strains/serotypes of same 
virus and/or different viral strains specific for 
different hosts 
 
US20120207786A1 Use of influenza virus like particle comprising 
specified influenza virus protein and specified 
influenza virus hemagglutinin and 
neuraminidase proteins in the preparation of 





US20120219584A1 Immunogen comprises nucleic acid molecule 
encoding a protein with influenza A subtype H1 
hemagglutinin glycan-shielded receptor binding 
domain A region and influenza A subtype H1 
hemagglutinin antigenic site, where site is not 
within region 
THE UNITED STATES OF 
AMERICA as represented by THE 
SECRETARY DEPARTMENT OF 
HEALTH,Bethesda,MD,US 
US20120219586A1 Adjuvanted influenza vaccine formulation, useful 
for prophylaxis of influenza infection or disease 
in subject, comprises peptidoglycan 
microparticles, and influenza virus antigen or its 
antigenic preparation 
 
US20120244185A1 New chimeric adenoviral expression vector 
comprising an expression cassette containing 
promoters useful for eliciting an immune 
response (mucosal immune response) against 
H1N1 influenza in mammals in mammals 
(human) 
Vaxart Inc.,San Francisco,CA,US 
US20120269852A1 Influenza vaccine for immunizing patient against 
influenza virus infection comprises combination 
of detoxified or non-toxic mutant of subunit A of 
AB type exotoxin, aluminum salt, and influenza-
specific antigen 
 
US5948410A New influenza surface antigen vaccine 
propagated on animal cell culture used to 
produce e.g. human, swine, equine and avian 
influenza vaccines avoids disadvantages 
associated with culturing on embryonated 
chicken eggs 
Duphar International Research 
B,Weesp,NL 
US6800288B2 Recombinant NS gene of an influenza A virus 
comprising a functional RNA binding domain and 
a gene sequence modification after nucleotide 
position 400 of the NS1 gene segment, useful for 





US7238349B1 New monovalent influenza vaccine, useful 
particularly for preventing infection by pandemic 
strains, contains low dose of egg-derived antigen 
SmithKline Beecham Biologicals 




US7521220B2 Producing an influenza virus or influenza viral 
protein for use as a vaccine by providing a cell 
with a sequence encoding a gene product of an 
adenoviral E1 gene and harvesting the influenza 
virus from the suitable medium or the cell 
Crucell Holland B.V.,Leiden,NL 
US8119337B2 Preparing an influenza vaccine from influenza 
virus grown in a culture of a mammalian cell line 
by testing the vaccine or culture for an infectious 
agent that can grow in the cell line but that does 
not grow in embryonated hen eggs 
GREGERSEN JENS-PETER 
US8163545B2 New recombinant adenovirus vector comprises a 
polynucleotide encoding at least one antigen of 
an avian influenza strain, useful for producing 
vaccines for eliciting an immune response 
against avian or pandemic influenza 
United States of America as 
represented by the Secretary of 
the Department of Health and 
Human Services Centers for 





US8288090B2 Preventing or treating infection caused by 
influenza A H1N1, H1, H2, H3, H5 or H7, involves 
delivering nucleic acid molecule encoding 
hemagglutinin or neuraminidase from pandemic 
influenza to subject 
Statens Serum 
Institut,Copenhagen S,DK 
VN22532A New immunogenic influenza composition, 
comprises an influenza virus antigen or antigenic 
preparation in combination with an oil-in-water 
emulsion adjuvant, useful for treating or 
preventing diseases caused by influenza 
infection 
 
VN23203A New monovalent influenza vaccine composition 
comprises low amount of influenza virus antigen 
from an influenza virus strain that is associated 
with a pandemic, useful for protecting a human 




WO2007065967A1 New vaccine composition containing HN antigen 
pairs of influenza A virus targeted against 
recombinant H5N2 type of influenza virus, useful 
for vaccinating against influenza A virus 
REMEDAL OY,FI | HEINO 
Pekka,FI 
WO2011138032A3 Immunogenic composition useful for inducing a 
protective immune response to an influenza 
infection in a mammal, comprises one or more 
peptides 
MAKSYUTOV Amir,RU | 
ARTEMEV Timur,GB | 
ANTONETS Denis,RU | 
BAKULINA Anastasia,RU | 
MAKSYUTOV Rinat,RU 
WO2012114323A1 Improving protective effect of seasonal or 
pandemic influenza vaccine, comprises 
vaccination of subject, prior to, or together with, 
administration of seasonal or pandemic vaccine, 
with synthetic or recombinant multimeric 
polypeptide 
BEN-YEDIDIA Tamar,IL | 
BIONDVAX PHARMACEUTICALS 
LTD.,IL | LOWELL George H.,IL 
   
Supporting Technologies Category 
 AU2011202991A8 New influenza hemagglutinin or neuraminidase 
variant polypeptide, useful in preparing a 
composition for treating or preventing infection 
caused by influenza virus 
US GOVERNMENT | 
MEDLMMUNE LLC 
AU2011253998A1 Replicating virus, e.g. adenoviruses, 
hepadnaviruses, or herpes viruses, in avian 
embryonic derived stem cells Ebx, useful as 
vaccine, comprises infecting cells with the virus, 
culturing infected cells, and harvesting the virus 
VIVALIS 
AU733191B2 Recombinant influenza haemagglutinin 
produced in baculovirus system avoids problems 
of growing virus in eggs and produces stable, un-
cleaved protein useful in vaccines 
PROTEIN SCIENCES CORP 
CN101560503B New influenza A virus Vero cell adapted strain 
named A/Yunnan/1/2005Va (H3N2), where the 
preserving number of the strain is CCTCC No: 
V200514, useful for preparing a Vero cell 
adapted strain of the epidemic strain 
INST MEDICAL BIOLOGY 
CHINESE ACAD MEDICA,CN 
 51 
 
CN101897966A Cynomorium songaricum immunological 
adjuvant useful in influenza vaccine, comprises 
Cynomorium songaricum extract and a carrier 
Chinese Academy of Sciences 
Kunming Institute of Botany,CN 
| Institute of Medical Biology 
Chinese Academy of Medical 
Sciences 
CN101899418A New isolated avian influenza virus comprising 
RNA in its genome, useful in vaccine for 
preventing avian influenza virus 
Shanghai Centre for Animal 
Disease Control and 
Prevention,CN 
CN101926994B Immunoadjuvant used in influenza vaccine, 
comprises turtle shell extract and carrier, and 
has low side effect and is prepared in simple, 
cost-effective and eco-friendly manner 
Institute of Medical Biology 
Chinese Academy of Medical 
Sciences,CN | Chinese Academy 
of Sciences Kunming Institute of 
Botany,CN 
CN101926995A Immunoadjuvant used in influenza vaccine, 
comprises Asparagus extract and carrier, and is 
safe and prepared in simple, cost-effective and 
eco-friendly manner 
Chinese Academy of Sciences 
Kunming Institute of Botany,CN 
| Institute of Medical Biology 
Chinese Academy of Medical 
Sciences 
CN102038949A Inactivated quad vaccine useful for 
pharmaceutical applications comprises 
inactivated Newcastle disease virus, chicken 
infectious bronchitis virus, chicken egg drop 
syndrome virus, bird flu virus (H9 subtype), and 
adjuvant 
Qingdao Yebio Bioengineering 
Co. Ltd.,CN 
CN102068695B  Qingdao Yebio Bioengineering 
Co. Ltd.,CN 
CN102078605A Influenza vaccine produced using infected Vero 
cell by preparing virus liquid vaccine by cleaning 
Vero cells, adding virus into maintenance 
medium, adding pancreatin to obtain virus 
supernatant and purifying liquid vaccine 
Jilin Yatai Bio-pharmaceutical 
Co. Ltd.,CN 
CN102139104A Inactivated trivalent vaccine, useful for 
Newcastle disease virus, avian influenza and 
infectious bursal disease virus causing diseases, 
comprises e.g. inactivated LaSota strain of 
Newcastle disease virus and YBF003 strain 




CN102293743A Lipid microsphere emulsion useful for treating 
pandemic influenza virus in children, comprises 
pharmaceutical grade oil, zwitterionic/non-ionic 
surfactant composition, antigen associated with 
pandemic influenza and aqueous solution 
Liaoning Chengda Biotechnology 
Co. Ltd.,CN 
CN102397540A A type avian influenza recombinant phage 
vaccine, comprises recombinant T7 phage as 
antigen 
Jiangsu Academy of Agricultural 
Sciences,CN 
CN102406931A Preparing pandemic influenza virus split vaccine 
comprises culturing NIBRG-14, inactivating by 
adding an inactivator containing e.g. an 
alkylating agent, filtering and concentrating virus 
liquid, purifying and freeze-drying vaccine 
product 
Chengdu Kanghua Biological 
Products Co. Ltd.,CN 
CN1313605C Gene recombinant fowl influenza virus D3/F-
R2/6 and its construction method 
Yangzhou University 
CN1644686B High yield strain of mammalian influenza virus, 
useful in preparing vaccine strains of influenza A 
INST BEIJING VIRAL DISEASE 
CONTROL & PRE 
EP1534845A1 Rescuing attenuated and/or recombinant 
orthomyxovirus, useful for the manufacture of 
live, attenuated vaccine, comprises delivering 
the resulting recombinant baculovirus genome 




EP2484757A1 Producing alpha-Gal expressing virus, e.g. 
influenza viruses, by introducing alpha 1,3-
galactose transferase gene into cell, inoculating 
virus into cell system and culturing viral infected 
cell system to obtain virus 
National University Corporation 









EP2491117A1 Preparing virus e.g. rotavirus, used e.g. as 
vaccine, comprises transfecting culture of host 
cells with expression construct encoding viral 
RNA molecule, adding cells to the transfected 




GB660109A  AMERICAN CYANAMID CO 
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IN201001689P4 Producing influenza virus, useful for producing 
vaccine against influenza, comprises 
administering a vaccine against influenza to 
chickens, activating embryogenesis in eggs of 
chicken, infecting eggs with influenza and 
harvesting virus 
 
IN201005447P4 Stabilizing influenza vaccine composition 
comprises diluting liquid bulk composition, 
subjecting regular droplets to freezing to form 
frozen regular spherical micropellets or particles, 
and drying 
 
IN201104719P2 Host cell useful for producing recombinant virus 
strains comprises expression construct encoding 
viral RNA molecule, where expression of the 
RNA molecule is controlled by pol I promoter 
which is not endogenous to host cell's 
taxonomic order 
 
JP03918949B2 Recombinant influenza haemagglutinin 
produced in baculovirus system avoids problems 
of growing virus in eggs and produces stable, un-
cleaved protein useful in vaccines 
PROTEIN SCI 
JP2007314538A Recombinant influenza haemagglutinin 
produced in baculovirus system avoids problems 
of growing virus in eggs and produces stable, un-
cleaved protein useful in vaccines 
PROTEIN SCIENCES 
KR1998081114A New influenza surface antigen vaccine 
propagated on animal cell culture used to 
produce e.g. human, swine, equine and avian 
influenza vaccines avoids disadvantages 
associated with culturing on embryonated 
chicken eggs 
 
KR593235B1 New influenza surface antigen vaccine 
propagated on animal cell culture used to 
produce e.g. human, swine, equine and avian 
influenza vaccines avoids disadvantages 






MX2009009565A New recombinant protein comprising 
hemagglutinin of influenza virus A H1N1-2009 
expressed in Escherichia coli, used as a vaccine 
or the main active ingredient of a vaccine against 
influenza A H1N1-2009 
ITESM 
MX207194B New influenza surface antigen vaccine 
propagated on animal cell culture used to 
produce e.g. human, swine, equine and avian 
influenza vaccines avoids disadvantages 
associated with culturing on embryonated 
chicken eggs 
 
RU2031941C1 Strain of virus A(H1N1) for prodn. of live 
intranasal influenza vaccine based on the 
epidemic virus A/Leningrad/92/89 (H1N1) 
NII GRIPPA RAMN 
RU2033424C1 Strain of influenza A (H3N2) virus used in prodn. 
of live intranasal vaccine for children and adults 
NII GRIPPA RAMN 
RU2065498C1 Strain Shangdong for prodn. of live influenza 
intranasal vaccine for children is useful in public 
health for prevention of influenza epidemics in 
children of age 3-14 
NIIEX MEDITSINY RAMN 
RU2078818C1 Viral strain used in preparation of active 
influenza vaccine is polymorphic strain used in 
intranasal influenza vaccine for adults 
NIIEX MEDITSINY RAMN 
RU2078820C1 Strain A/47/Peking/92/3 (H3N2) GISK No. 104 is 
polymorphic and used for live intranasal 
influenza vaccine used by children 
NIIEX MEDITSINY RAMN 
RU2084524C1 Influenza A virus strain A/17 
Texas/91/1/3(H1N1) Gisk No. 102 is used in the 
manufacture of live, intranasal influenza vaccine 
for adults 
NIIEX MEDITSINY RAMN 
RU2159812C1 Influenza virus strain a/17/sydney/97/76 (h3n2) 
for production of live influenzal intranasal 
vaccine for adults 
NII EHKSPERIMENTAL | NOJ 
MEDITSINY RAMN 
RU2285723C2 Influenza virus strain A/Wyoming/3/03 (H3N2) 
for production of living influenza intranasal 
vaccine for infants and adults 
GU NII EHKSPERIMENTAL NOJ 
MEDI 
RU2307161C2 Influenza virus strain for living influenza 
intranasal vaccine for infants and adults 
GU NII EHKSPERIMENTAL NOJ 
MEDI 
RU2307162C1 Influenza virus strain for influenza intranasal 
vaccine for infants and adults 




RU2413765C1 Vaccine strain of flu virus 
a/17/california/2009/38 (h1n1) for profuction of 
live influenza intranasal vaccine for adults and 
children 
UCHREZHDENIE ROSSIJSKOJ 
AKADEMII MED NAUK NII 
EHKSPERIMENTAL NOJ 
MEDITSINY SEV ZAP OTDEL 
RAMN NIIEHM 
RU2428476C1 Reassortant rn a9-swine a(h7n1) influenza virus 
strain for neuraminidase antibody assay in 
influenza infection and vaccination 
UCHREZHDENIE ROSSIJSKOJ 
AKADEMII MED NAUK NII 
EHKSPERIMENTAL NOJ 
MEDITSINY SEV ZAP OTDEL 
RAMN NIIEHM 
RU2457243C1 Cultivated hybrid cell strain of mouse mus. 
Musculus-1e7 producer of monoclonal antibody 
immunoresponsive to haemagglutinin protein of 
pandemic influena virus a/iiv-
moscow/01/09(h1n1)sw1 
FEDERAL NOE G BJUDZHETNOE 
UCHREZHDENIE NII 
VIRUSOLOGII IM D I 
IVANOVSKOGO MIN 
ZDRAVOOKHRANENIJA I SO 
RU2457245C1 Reassortant rem8-vaccine strain of suptype h1n1 
influenza a virus What is offered is a vaccine 
strain of A ReM8 (H1N1) virus deposited in the 
State Collection of Viruses No. 2632 
FEDERAL NOE G BJUDZHETNOE 
UCHREZHDENIE NII 
VIRUSOLOGII IM D I 
IVANOVSKOGO MIN 
ZDRAVOOKHRANENIJA I SO 
RU2458124C2 New strain of influenza A virus subtype H3N2 
useful for producing composition containing 
inactivated influenza virus for treating influenza 
FEDERAL NOE G BJUDZHETNOE 
UCHREZHDENIE NII GRIPPA MIN 
ZDRAVOOKHRANENIJA I 
SOTSIAL NOGO RAZVITIJA RF 
SU1003539A1 Influenza virus strain A-17-42-3 H3N2 is used for 
prodn. of live influenza vaccine 
POLEZHAEV F I | 
ALEKSANDROVA G I | 
BUDILOVSKIJ G N | 
GARMASHOVA L M | KOVAL T A 
| GRUNIS A M | KLIMOV A I | 
SLEPUSHKIN A N | MEDVEDEVA 
T E | GENDON YU Z 
SU1219644A1 Influenza virus strain a-f-59-1 is used for prepn. 
of inactive anti-influenza vaccine. 
NIIEX MEDITSINY | MO NII 
VIRUSNYKH PREPARATOV | LE 
NII VAKTSIN SYVOROTOK 
SU1838404A3 Influenza A virus strain H3N2 is used for the 
prodn. vaccines for children which are 
administered nasally, is useful for the prevention 
of influenza epidemics in children 
NIIEX MEDITSINY AMN SSSR 
SU833260B Prodn. of vaccine strain of influenza virus by 
crossing virulent and heat sensitive viral strains 





TW570803A New influenza surface antigen vaccine 
propagated on animal cell culture used to 
produce e.g. human, swine, equine and avian 
influenza vaccines avoids disadvantages 
associated with culturing on embryonated 
chicken eggs 
 
US20090202589A1 Fermenter vessel for culturing cells and for 
preparation of virus vaccine, comprises view 
port provided in outside wall for inspecting 
processes within vessel volume, and heating 
device on transparent member of view port 
 
US20090326978A1 Combination anti-viral therapy stockpiling 
method for e.g. pandemic influenza, involves 
coordinating storage of therapeutic doses of 
antiviral agents to enable shipment of 
therapeutic doses within preset hours for each 
other 
 
US20110177121A1 New composition comprises an immunogenic 
epitope of influenza that is not 
immunodominant as in a wild type virus, useful 




US20110212129A1 Producing influenza virus, useful for producing 
vaccine against influenza, comprises 
administering a vaccine against influenza to 
chickens, activating embryogenesis in eggs of 
chicken, infecting eggs with influenza and 
harvesting virus 
SANOFI PASTEUR S.A.,Lyon,FR | 
MERIAL LIMITED,Duluth,GA,US 
US20110217330A1 Degrading host cell nucleic acids associated with 
virus or its viral antigen produced by cell culture, 
useful to e.g. treat influenza infection, comprises 
degrading the nucleic acids with an 
endonuclease or a DNA alkylating agent 
 
US20110243987A1 Immunizing a human against influenza virus 
infection by selecting a human who was 
previously vaccinated with a monovalent first 
vaccine composition, and administering a 
second vaccine composition comprising an 
influenza virus antigen 
GlaxoSmithKline Biologicals s.a. 
 57 
 
US20120189656A1 Host cell useful for producing recombinant virus 
strains comprises expression construct encoding 
viral RNA molecule, where expression of the 
RNA molecule is controlled by pol I promoter 
which is not endogenous to host cell's 
taxonomic order 
 
US20120219587A1 Producing split influenza virus preparation used 
for pharmaceutical composition for preventing 
and/or treating diseases caused by influenza, by 
fractionating preparation, adding Triton X-100 to 
preparation and filtering preparation 
 
US20120294879A1 New polypeptide comprising lysosome-
associated membrane protein-1 (LAMP-1) 
luminal sequence, a segment of influenza A 
protein, and LAMP transmembrane and 
cytoplasmic tail, useful in e.g. immunizing 
human against human influenza A virus 
NATIONAL UNIVERSITY OF 
SINGAPORE,Singapore,SG | THE 
JOHNS HOPKINS 
UNIVERSITY,Baltimore,MD,US 
US4206287A Influenza virus mutant repeated culture and 
isolation immuno vaccins against future virus 
mutants 
Agence Nationale de 
Valorisation de la Recherche 
(ANVAR),Neuilly sur Seine,FR 
US6245532B1 Expressing a protein e.g. recombinant influenza 
virus hemagglutinin comprising using a vector 
encoding a polypeptide comprising a baculovirus 
signal peptide and a baculovirus expression 




US8148132B2 Replicating virus, e.g. adenoviruses, 
hepadnaviruses, or herpes viruses, in avian 
embryonic derived stem cells Ebx, useful as 
vaccine, comprises infecting cells with the virus, 
culturing infected cells, and harvesting the virus 
Vivalis,Roussay,FR 
US8163545B2 New recombinant adenovirus vector comprises a 
polynucleotide encoding at least one antigen of 
an avian influenza strain, useful for producing 
vaccines for eliciting an immune response 
against avian or pandemic influenza 
United States of America as 
represented by the Secretary of 
the Department of Health and 
Human Services Centers for 







US8282937B2 New reassortant influenza virus, useful in 
preparing a vaccine comprising the reassortant 
influenza virus for preventing influenza virus 
infection 
The Regents of the University of 
Michigan,Ann Arbor,MI,US 
VN24155A Producing influenza virus, useful for producing 
vaccine against influenza, comprises 
administering a vaccine against influenza to 
chickens, activating embryogenesis in eggs of 
chicken, infecting eggs with influenza and 
harvesting virus 
 
WO2008138120A1 Assessing the anti-influenza effect of an agent of 
interest by incubating the particles with cells 
capable of infection, and comparing the 
infection rate of the virus-like particles in the 
presence and absence of the agent 
UNIVERSITY OF MANITOBA,CA | 
HER MAJESTY THE QUEEN IN 
RIGHT OF CANADA AS 
REPRESENTED BY THE MINISTER 
OF HEALTH,CA | YAO Xiojian,CA 
| AO Zhujun,CA | KOBINGER 
Gary,US | KOBASA Darwin,CA 
WO2011133997A1 Use of gamma-irradiated influenza virus 
comprising Chalmers strain backbone of specific 
proteins for treating influenza virus infection, 
and for inducing cross-protective immunity 
against multiple influenza virus subtypes in a 
subject 
GAMMA VACCINES PTY 
LIMITED,AU | MULLBACHER 
Arno,AU | ALSHARIFI 
Mohammed,AU | HIRST Tim,AU 
WO2012009790A1 Use of second unique hemagglutinin and 
pathogen e.g. HIV1 protein for inducing a cross-
protective antibody response in a subject that 
has been previously subjected to a first unique 
hemagglutinin and pathogen protein 
SCHRADER John W.,CA 
WO2012050229A1 New recombinant vaccinia virus used in 
pharmaceutical composition for preventing 
and/or treating H5N1 virus and H1N1 virus, 
comprises expression promoter and 
complementary DNA encoding highly pathogenic 
avian influenza A (H5N1) virus 
TOKYO METROPOLITAN 
INSTITUTE OF MEDICAL 
SCIENCE,JP | KIDA Hiroshi | 
MURAKAMI Toshio,JP | YASUI 
Fumihiko,JP | KOHARA 
Michinori,JP | NATIONAL 
UNIVERSITY CORPORATION 
HOKKAIDO UNIVERSITY,JP | THE 
CHEMO-SERO-THERAPEUTIC 




WO2012088428A1 New virus-like particle comprising a recombinant 
influenza virus hemagglutinin protein, useful for 
inducing substantial immunity to an influenza 
virus infection, and for treating and/or 
preventing influenza infection 
NOVAVAX INC.,US | SMITH 
Gale,US | LIU Ye,US | MASSARE 
Michael,US | SINGHVI Rahul,US 
ZA201001480A Producing influenza virus, useful for producing 
vaccine against influenza, comprises 
administering a vaccine against influenza to 
chickens, activating embryogenesis in eggs of 
chicken, infecting eggs with influenza and 
harvesting virus 
 
ZA201006225A Stabilizing influenza vaccine composition 
comprises diluting liquid bulk composition, 
subjecting regular droplets to freezing to form 







The ITTI team used genome quest for this patent landscape report according to the methodology 
previously described.  Find sequences from PubMed proved to be an arduous task as many of the 
relevant articles did not disclose sequence that we could use for a GenomeQuest search.  As 
such, few sequences were found through PubMed.  
 
Additionally the ITTI team pulled sequences directly from patents whenever they were disclosed 
within the document.  However, the occurrence of sequences disclosure within a patent 
document was quite rare and as such many of the GenomeQuest searches were not performed 
from sequences acquired in this manner.  
 
For this report, the second approach of acquiring sequences from a relevant database proved to 
be the main source of sequences used in GenomeQuest searches.  The main database used was 
the influenza research database.
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  Both genetic and protein sequences were acquire from the 
database for GenomeQuest searches.  The sequences acquired were from influenza viruses that 
were found in birds or pigs and additionally with hemagglutinin or Nneuraminidase subtypes of 
interest.  







With the sequences found, GenomeQuest searches were used on these sequences.  For sequences 
acquired from patent documents, the search results, when sorted by the percentage of conformity 
to the sequenced searched, the relevant results were patents generally from the same company or 
a subsidiary of the company.  For sequences from the database, many relevant patents were 
found at all levels of conformity.  While GenomeQuest did find many relevant patents, these 
patents were already identified through keyword searches in either Thomson Innovation or Total 







Categories of Analysis  
 
Analysis is presented for the two major relevant categories, Vaccines and Supporting 
Technologies.  The subcategories under each of these major headings were pooled together and 
analyzed as a group in order to present a large enough dataset for generating meaningful results.  
Parallel analytics were generated for the two major categories, and comparisons are given.  The 
exceptions were the analysis for multi-jurisdictional filings, which was performed for only 
vaccine documents, and the analysis of top assignees, which was performed with both major 
groups pooled together.  Platform technologies were not analyzed. 
 
ThemeScape Map of Derwent Data 
 
A graphical representation of the results was generated using ThemeScape, a tool within the 
Aureka platform initially developed by Aurigin Systems, Inc., and now available through 
Innovation.
125
  ThemeScape creates a virtual “map” of patent data by extracting keywords from 
the documents and plotting those topics in relation to one another.  “Islands” are formed by 
closely related topics and “mountains” are formed when a large number of documents all contain 
the same or similar keywords.  Gaps between distantly related topics represent an “ocean.”  
ThemeScape is a powerful tool which can reveal relationships within a large dataset that are not 
otherwise apparent. 
 
ThemeScape provides options for the sources of keywords within each document.  The maps 
presented below were derived from the DWPI title, DWPI abstract, and claims in English from 
one representative of each INPADOC family.  Extracting data only from representative 
documents prevents large patent families from skewing the results and gives equal weight to 
each invention.  Not all references had this DWPI data in their records, so the maps represent a 
subset of the entire datasets. 
 
The map in Figure 10 shows the topics found with documents coded to the vaccine category.  
Many of the topics agree with the coding criteria.  At the center right of the map is a mountain 
labeled “split influenza” and “pandemic combination,” which would represent subunit vaccines 
for a combination of pandemic and seasonal influenza.  The bottom center of the map has a 
mountain labeled “live, intranasal, embryos” which would indicate live virus vaccines where the 
virus is grown in eggs (chicken embryos) and then administered intranasally.  Since pandemic 
influenza strains cannot be propagated in eggs because the viruses are lethal to the embryos, the 
viruses must be attenuated or recombinant (reasserted) so they do not kill the embryos.  A peak  
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indicating as much is immediately adjacent to the whole virus vaccine mountain.  Other methods 
of avoiding this problem of lethality is to express subunits in plants (upper center) or insect cells 
(center left).  Antigens could also be expressed as polypeptides, possibly in bacteria or 
mammalian cells, although these expression systems are not indicated. 
 
The center right and upper right portion of the map has keywords related to the formulation of 
vaccines, such as “solution, mixing, adding,” and “oil-in-water emulsion.”  Carriers such as 
“lipid vesicles” are also represented in the upper center of the map.  The center and upper left of 
the map represents DNA constructs, or “vectors,” used to generate recombinant viruses or 
recombinant subunits.  The topics in the upper left such as “plasmid,” “chimeric promoter,” and 






 Figure 11.  ThemeScape map of the representative documents from the 750 vaccine supporting 
technology families. 
 
The map of the vaccine documents can be contrasted to the map of the supporting technologies 
shown in Figure 11.  The supporting technologies map contains more “islands,” representing the 
broader range of technologies in this category as compared to vaccine documents.  The upper left 
and upper center sections of the map have keywords related to the subcategory of methods of 
making vaccines, such as “harvesting” virus from “eggs” and purifying the virus by “filtration,” 
“centrifugation” of the “allontoic fluid” to isolate the virus, and “treating virus-containing fluid” 
and then adding “cationic detergent.”  Just below those peaks are other methods of preparing 
vaccines such as “lyophilization” and “isolated” virus from “serum-free medium.” 
 
The bottom left section of the map is an island which indicates methods of producing virus or 
viral subunits, such as “producing negative strand RNA” viruses, “cDNA transcription,” and 
“nucleic acid vectors.”  Novel viruses useful in vaccines are represented by the “attenuated/cold 
adapted” peak in the center of the map.  Most of the Russian documents in this subcategory 
mentioned use of the viruses to immunize children.  The “amino acid/peptide” peak at lower 
right would correspond to recombinant subunits, and the “coding/noncoding” peak just beneath 
would represent DNA constructs used to produce the recombinant subunits.  At extreme lower 
left are veterinary vaccines, such as for “equine” influenza.  Tetanus toxin is an adjuvant in some 
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of these vaccines.  “Canarypox virus” is used as a carrier for influenza antigens in some bird 
vaccines. 
 
In summary, the two maps are very different which would be expected if the coding of the 
documents successfully placed the majority of the documents in the correct subcategories.  The 
labels on the peaks also correspond to the subcategories.  These maps not only reveal the 
relationships between the different technologies in each group but they also validate the 
document coding protocol which is the basis for the further analytics presented below. 
 
 
Priority Country v. Document Count 
 
Important questions to ask in the analysis of patent data is “where does the technology come 
from?” and “where is the technology being used?”  The first question can be answered by 
analyzing the priority country, which is the country in which the priority patent document is 
filed.  Further data can be gleaned from the country in which the top assignees are based, which 
is presented below.  The second question can be answered by analyzing the multi-jurisdictional 
filings, which also follows below. 
 
Although information regarding the priority country is useful, it does not necessarily indicate the 
source of the technology.  For example, publications HK1154041A0 and HK1156969A0 are 
assigned to Medicago, Inc., a Canadian company.  However, Medicago
126
 tends to file 
applications first in the U.S., and the priority documents for both of these references are U.S. 
applications.  Also, IN200503876P1 is assigned to a group of French entities - CNRS, the 
Pasteur Institute, and the University of Paris - but the priority document is a Canadian 
application.  Thus, some assignees file first in other jurisdictions, perhaps to take advantage of 
that country’s patent laws or because the patent will be practiced primarily in that country.  For 
example, Medicago has a manufacturing plant in the U.S., although its research facility is 
apparently in Canada.  
 
Most documents have priority data recoded in the Innovation database, but a few do not.  In the 
majority of cases, priority data can be found through patent family members.  When possible, 
priority information was added to the data.  Such manually corrected data is indicated by 
highlighted cells in the files presented in Appendices C and D. 
 
The priority country information for vaccine patent documents is presented in Figure 12.  The 
United States (US) is by far the largest source of priority documents.  China (CN) and Great 
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 http://www.medicago.com/.  
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Britain (GB) are secondary sources, followed by Russia (RU) and the former Soviet Union (SU), 
the European Patent Office (EP), Japan (JP), and Korea (KR). 
 
The priority country information for the supporting technologies documents, shown in Figure 13, 
is very similar to that of vaccine documents.  All the countries listed above were also the source 
of supporting technologies.  The major difference is that France (FR) is a more prominent source 
of supporting technologies than complete vaccines. 
 
 









































Vaccine Families by Priority Country 
Figure 12.  The priority country for 
each patent family in the vaccine 
category (570 total) is indicated.  
The countries are represented by the 
two-letter codes can be found on the 










Top Vaccine Families for Multi-Jurisdictional Filings 
 
Vaccine technologies that have been transferred to the most other countries were calculated by 
first determining the size of each INPADOC family within the vaccine document dataset.  This 
data may be slightly skewed because applications filed in certain jurisdictions are not recorded as 









































Supporting Technologies Families by Priority 
Country 
Figure 13.  The priority country for 
each patent family in the 
supporting technologies category 
(750 total) is indicated.  “nd” 
means the priority country was not 
determined for a few families. 
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being members of INPADOC families.
127
  These jurisdictions include Hong Kong, India, 
Mexico, the Philippines, Portugal, Tawain, and Viet Nam.  For this reason, the TotalPatent 
Extended Family was also retrieved for each of the largest INPADOC families to try to capture 
family members from these jurisdictions.  It is still possible these jurisdictions remain under-
represented in the dataset.  The extended family was not retrieved for all documents because the 
export functions of TotalPatent do not allow this data to be captured in a convenient manner.  
The number of jurisdictional filings was determined by combining the INPADOC, DWPI, and 
TotalPatent families for each representative document. 
 
Twenty-one representative family members had INPADOC families with 29 or more members.  
The top family was represented by US20110180430A1, a relatively recent document whose 
family already contains 90 members.  However, the INPADOC family represented by 
US5948410A has been filed in 32 different jurisdictions, which is the most of this group.  Four 
families are assigned to GlaxoSmithKline and two to Novartis.  No other assignee is represented 
multiple times.  The oldest family is represented by US3953592A, which was filed in 1973.  
Three applications published in 2012 are also on the list.  These families are shown in Table III, 
and the details of each family can be found in Appendix E. 
 
Table III.  Top Multi-Jurisdictional Filings per INPADOC Family in the Vaccine Category. 
Publication 
Number 
Assignee Size of 
INPADOC 
Family 
Filing Jurisdictions Total 
Number of 
Jurisdictions 
US20110180430A1 CHIRON SRL | 
NOVARTIS  
90 AT | AU | BR | CA | CN| DE 
| DK | EA | EP | ES | JP | KR 
| NZ | PL | PT | SI | US | 
WO | IN 
19 
US20110287054A1 GLAXOSMITHKLINE  76 AR | AU | BR | CA | CN | EA 
| EP | GB | IL | JP | KR| MA 
| MX | NO | NZ | PE | SG | 
US| WO | ZA| IN | TW 
22 
US20120207786A1 NOVAVAX 69 AT | AU | BR | CA | CN | DK 
| EP | ES | HK | IL | JP| KR | 
MX | NZ | PT | RU | SG | US 






54 AR | AT | AU | BR | CA | CN 
| CO | CZ | DE | DK | EP | ES 
| GB | HK | HU | IL | JP| MX 
| MY | NO | NZ | PL | PT | 
SI | TW | US | WO | ZA | KR 
| IN | PH 
31 
                                                 
127
 See also Notes on Patent Families in Appendix M. 
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US8309099B2 St. Jude Children's 
Research Hospital 
54 AT | AU | BR | CA | CN | DE 
| DK | EA | EP | ES | HK | 
HU | IL | JP | KR | MX | NO 
| NZ | PL | PT | SI | US | 
WO | ZA | IN 
25 
US4140762A SANDOZ SA 53 AT | AU | BE | CA | CH | CS 
| DE | DK | ES | FI | FR | GB 
| HK | HU | IE | IL | JP | MY 
| NL | NO | PH | PL | SE | 




Medical Center; St. 
Jude Children's 
Research Hospital 
51 AT | AU | CA | DE | DK | EP 
| ES | JP | PT | US | WO 
11 
US20110293650A1 MEDICAGO INC 49 AU | CA | CN | CR | EA | EP 
| IL | IN | IS | JP | KR | MA | 
MX | NZ | RU | US | WO | 





47 US | AR | AT | AU | BR | CA 
| CN | CZ | DE | DK | DZ | 
EP | ES | GR | HK | HR | HU 
| ID | IL | JP | MX | NO | NZ 
| PL | PT | RU | SI | SK | TR 
| TW | ZA | KR 
32 





45 AT| AU | CA | CN| DE | EP | 
ES | HK | JP | KR | MX | US 
| WO | ZA | IN 
15 
US20080038294A1 ABBOTT 
BIOLOGICALS BV | 
SOLVAY 
BIOLOGICALS BV  
39 AR | AT | AU | BR | CA| CN 
| DE | DK | EA | EP | ES | 
HR | IL | JP | KR| MX | MY | 
NO | PT | SI | TW | US | WO 
| ZA | IN |  VN 
26 
US8119337B2 CHIRON BEHRING 
GMBH & CO | 
NOVARTIS 
39 AT | CA | DE | DK | EP | ES | 
HK | HR | JP | PT | RS | SI | 
US | WO 
14 
US20120034264A1 MEDIMMUNE | US 
NAT INST OF 
HEALTH 
36 AU | CA | EP | ES | JP | US | 
WO 
7 
US20110129497A1 PEPTIMMUNE INC 34 AP | AU | CA | CN | EP | IL | 
JP | KR | MX | NZ | US | WO 
12 
US20120219575A1 PEPTCELL LTD 34 AP | AT | AU | BR | CA | CN 
| DK | EA | EP | ES | GB | IL 
| JP | KR | MX | NO | NZ| PL 





US20040087521A1 MERCK & CO INC 33 US | AU | BG | BR | CA | CN 
| CZ | DZ | EP | FI | HR | HU 
| IL| JP | NO | NZ | PL | RO 
| SG| SI | SK | WO | ZA | ID  
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LTD 
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| EP | ES | GB | HK | JP | PT 
| US | WO 
14 
US20080260781A1 GLAXOSMITHKLINE  31 AT | AU | CA | DE | EP | ES 
| HK | IL | JP | NO | US | 
WO 
12 
US20030124145A1 MERIAL  29 AR | AU | BR | CA | CN | CO 
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| JP | MA | NZ |  US | WO | 
MX | KR | IN 
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| NL | NO | SE| ZA | PT 
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Global Filing Trends for Influenza A Virus Vaccines 
 
The previous section assessed filing trends for individual family trends.  The entire vaccine 
category was analyzed to determine the jurisdictions in which the entire vaccine population were 
filed.  The INPADOC and DWPI patent families were combined for each reference document, 
and each jurisdiction was counted only once per family.  For example, if a representative 
document had three European Patent Office applications, the EPO was counted once for that 
family.  The TotalPatent families were not incorporated into this dataset, due to the difficulties 
with exporting such data.  Thus, certain jurisdictions such as India, Taiwan and the Philippines 
may be under-represented. 
 
Of over 230 possible different jurisdictions in which patent applications could potentially be 
filed, influenza vaccine families were filed in a total of 68 jurisdictions.  As shown in Figure 14, 
North America and Europe are popular locations for assignees to seek protection for influenza 
vaccine inventions.  Of Asian countries, China, India, Japan, South Korea (i.e. the Republic of 
Korea), Vietnam, Singapore, and Hong Kong were targets for filing.  Most families were also 
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Figure 14.  Distribution of 
jurisdictional filings by vaccine 
patent families.  This data is also 







Figure 15.  Global filing trends by country.  The number of patent families that have sought 
protection in a given country are indicated by colors.  Countries shown in white have no 
identified filings among the 570 influenza vaccine patent families.  Multijurisdictional agencies, 
such as WIPO and the EPO, are not indicated.   
 
 
poorly represented, and no filings were done in any African country other than South Africa.  
Countries are only shown in Figure 14 if at least one filing occurred in that country. 
 
The jurisdictions where each patent family chose to seek patent protect was also plotted on a 
world map (see Fig. 15, above).  Each jurisdiction is indicated once per family.  For example, if a 
given patent family filed three U.S. applications, the United States was counted once for that 
family.  Greenland was considered part of Denmark for this analysis.  Also, the former 
Yugoslavia was indicated under Serbia and Montenegro, the former Czechoslovakia under the 
Czech Republic, and the former Soviet Union under Russia.  Multijurisdictional agencies were 
not plotted.  Nearly 70% of patent families had filed PCT applications with WIPO, so excluding 
PCT filings probably did not skew the results, as each country was affected equally.  Also, since 
the map only indicates countries where PCT applications entered the national phase, the map 
gives a more accurate portrayal of the jurisdictions in which assignees are most interested.  
However, exclusion of filings at the European Patent Office (EPO), probably does leave some 
European countries slightly underrepresented on the map.  Other multijurisdictional agencies not 
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indicated on the map are the Eurasian Patent Office (EAPO)
128
 which consists of countries 
belonging to the former Soviet Union and in which 20 patent families filed, the African Regional 
Intellectual Property Organization (ARIPO)
129
 which currently represents 18 nations and in 
which seven patent families filed, and the Cooperation Council for the Arab States of the Gulf 
(GCC)
130
 which represents six nations on the Arabian peninsula and in which two patent families 
filed.  Due to the time-consuming nature of this analysis, only influenza vaccines patent families 
were analyzed and plotted as above. 
 
The map demonstrates that the majority of patent families file in just a few countries.  The top 
nations for filings, indicated in red, are Australia, Canada, China, Japan, the Republic of Korea 
(South Korea), and the United States.  Secondary target nations, indicated in purple, are Brazil, 
Germany, India, Mexico, and New Zealand, followed by a group (in blue) that includes Austria, 
Norway, Russia, Spain, and South Africa.  A final group (in green) includes the Philippines, 
Vietnam, and several European nations.  No other nation had more than 20 patent family filings.  
Filings were particularly sparse in South America and Africa. 
 
Top Assignees by Patent Document Count 
 
Assignee data for patent documents is often inaccurate.  The patent rights could be sold to 
another assignee, who does not record the assignee.  Also, a company holding the rights changes 
its name or is sold in toto and new assignments are not recorded.  Some companies do not record 
an assignment until a patent is allowed, so published applications that are later abandoned or 
rejected do not have assignment data.  Outside of the U.S., university faculty members retain 
rights in their inventions so the name of the university is not given on the patent document.  
None of the patent databases maintain accurate updates for such changes or account for such 
missing data. 
 
Correction of patent assignee information must be performed manually.  While this represents a 
burden on clinic members’ time, such information would is invaluable to the use of the clinic 
report.  Accurate assignee information is essential in order for the report data to be updated, and 
so the correct owners of the technologies can be contacted for licensing inquiries. 
 
The main protocol for correcting assignee names is to use Google, searching for the company 
website or new releases about the company.  Business Week
131
 is a great source of information, 
as are technology-specific business reporters such as Fierce Biotech
132
.  These sources reveal the 
                                                 
128
 http://www.eapo.org/en/.  
129
 http://www.aripo.org/.  
130
 http://www.gcc-sg.org/eng/.  
131
 http://www.businessweek.com/.  
132
 http://www.fiercebiotech.com/.  
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current accurate name of the company listed as the assignee or whether the company is now a 
wholly-owned subsidiary of a larger company. 
 
If no information was readily obtainable, the assignee was searched using Innovation, restricting 
the date field to after the publishing date of the known document.  The Derwent Assignee field 
may have another assignee commonly listed with the company being researched.  A Google 
search of the two names together sometimes revealed a link between the two, such as a name 
change or an acquisition.  The Derwent assignee code
133
 is another source of assignee 
information.  Other companies may be linked to the same code, such as ASTR being used for 
both AstraZeneca and its acquired company MedImmune. 
 
If the only information available is the inventor name(s), then the document was located on 
Google Patent
134
.  This website has hyperlinks to other patent documents by the same inventor 
which may have assignee data recorded.  The name of the inventor was also searched on Google 
to find an association between the inventor and a particular company.  To make the search more 
accurate, the search includes both the inventor’s name and some keywords from the patent 
document.  LinkedIn
135
 and other networking websites are another source of information, and 
can be especially useful if an inventor is associated with multiple companies.  Typically the date 
of the application can be associated with a date range for when the inventor was working for one 
company rather than another.  Since patent applications can be filed months if not years after the 
date of the invention, this latter method was used with caution. 
 
Using the above methodology, the assignee information for each relevant document in the 
vaccine and supporting technologies categories was manually corrected as accurately as possible.  
The results were then sorted on assignee names to reveal the number of patent families 
associated with each assignee.  The two categories were analyzed together so a single list of 
assignees was generated, which is presented in Table IV. 
 
Twenty-one assignees had seven or more patent families each.  While the top four assignees – 
Novartis, GSK, Pfizer, and U.S. Merck - are for-profit companies, half of the assignees (12) are 
government agencies or non-profit institutions.  More assignees (7) are based in the United 
States than any other country.  Three institutions are located in China, and two each are based in 








 www.google.com/patents.  
135
 http://www.linkedin.com.  
 74 
 
Table IV.  Assignees with the Most INPADOC Patent Families in the Vaccines and Supporting 
Technologies Categories Combined (1,320 Families). 




Novartis 33 CH 
GlaxoSmithKline 25 GB 
Pfizer 25 US 
Merck and Co. (Merck Sharpe & Dohme) 23 US 
Nauchno-issledovatel'skij institut ehksperimental'noj meditsiny 
RAMN (Scientific Research Institute of Experimental Medicine, 
RAMS) 
23 RU 
Sanofi 21 FR 
AstraZeneca 20 GB 
University of Wisconsin 18 US 
US Department of Health 16 US 
Baxter International 15 US 
Saint Jude's Hospital 15 US 
Chinese Academy of Agricultural Sciences 14 CN 
Chinese Academy of Sciences 11 CN 
Kaketsuken 9 JP 
Institute of Medical Biology Chinese Academy of Medical 
Sciences 
8 CN 
Ministry for Food Agriculture, Forestry and Fisheries (Korea) 8 KR 
Mount Sinai Hospital 8 US 
Boehringer Ingelheim 7 DE 
Choong and Vaccine Laboratory 7 KR 
Ministry of Health, Labour and Welfare (Japan) 7 JP 
Vsesoyuznyj Nauchno-Issledovatelskij Institut Grippa (Union 




Top Inventors by Patent Document Count 
 
Of all patent data, inventor names are probably the most error-prone.  Inventor names do not 
change as assignee names tend to do, but inventor names are listed in a number of different 





  Names may be misspelled.
137
  Last names may be hyphenated or the hyphen may 
be absent.
138
  First and last names may even be switched.
139
   
 
Because of these errors, analysis of inventors using the databases is extremely inaccurate, as 
those calculations treat each variant of a name as a different inventor.  Thus, inventor names 
were reviewed manually and corrections made when possible.  The DWPI Inventor field lists 
alternative versions of inventors’ names, although sometimes more research is needed to 
determine which one of those variants is the correct name.  The most accurate source of inventor 
names is the scientific literature, which, unlike patents, is carefully edited prior to publication. 
 
Table V lists 30 inventors who each was an inventor of four or more patent families with the 
vaccines category.  The assignees associated the inventors are also given.  Curiously, this list of 
top inventors does not match the top assignee data, as only one Novartis inventor appears on the 
list and no GSK inventors are present.  The top five inventors are all Russian.  Complete inventor 
data for the vaccine category are given in Appendix H. 
 
 
Table V.  Top Inventors of Vaccine Patent Families. 
Standarized Inventor Name Number of 
Documents 
Assignee - DWPI 
Aleksandrova,  Galina 
Ibragimovna 
27 A MED EXPER MED RES INST 
Rudenko, Larisa Georgievna 24 A MED EXPER MED RES INST 
Klimov, Aleksandr I 16 A MED EXPER MED RES INST 
Kiseleva, Irina Vasil Evna 15 A MED EXPER MED RES INST 
Romanova, Julia 8 A MED EXPER MED RES INST| AVIR GREEN HILLS 
BIOTECHNOLOGY TRADE AG | POLYMUN SCI 
IMMUNBIOLOGISCHE FORSCHUNG 
Egorov, Andrej 7 POLYMUN SCI IMMUNBIOLOGISCHE FORSCHUNG | AVIR 
GREEN HILLS BIOTECHNOLOGY RES AG 
Barrett, P. Noel 6 BAXTER HEALTHCARE SA 
Kistner, Otfried 6 BAXTER HEALTHCARE SA 
Webster, Robert G. 6 WYETH | ST JUDE CHILDREN'S RES HOSPITAL 
Arnon, Ruth 5 YEDA RES & DEV CO LTD 
Kawaoka, Yoshihiro 5 WISCONSIN ALUMNI RES FOUND 
                                                 
136
 An example from the vaccine inventor list is Galina Ibragimovna Aleksandrova, who is also listed as Galina I. 
Aleksandrova and G. I. Aleksandrova. 
137
 RU2319744C2 misspells Aleksandrova’s middle name by dropping the “A” at the end. 
138
 For example, Derwent information shows at least five different versions of Wilson Romero Capparros-
Wanderley’s name.  See US20120219575A1. 
139
 Compare Robert G. Webster’s name on US8293247B2 and CA813864A. 
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O'Hagan, Derek 5 CHIRON CORP | NOVARTIS VACCINES&DIAGNOSTICS INC 
Polezhaev, Fial I 5 EXPER MEDICAL RES | KALIN SANITARY EPIDEMY | VIRUS 
MEDICAMENTS RES 
Sambhara, Suryaprakash 5 AVENTIS PASTEUR LTD | CONNAUGHT LAB LTD | PURDUE RES 
FOUND 
Seong, Baik Lin 5 BIOTRION CO LTD | PROTHEON CO LTD 
Ben-Yedidia, Tamar 4 YEDA RES & DEV CO LTD | BIONDVAX PHARM LTD 
Chatfield, Steven Neville 4 ARCHIMEDES DEV LTD | DANBIOSYST UK LTD | MEDEVA 
HOLDINGS BV | WEST PHARM SERVICES DRUG DELIVERY & 
CLIN 
Dorner, Friedrich 4 BAXTER HEALTHCARE SA 
Ferko, Boris 4 POLYMUN SCI IMMUNBIOLOGISCHE FORSCHUNG | AVIR 
GREEN HILLS BIOTECHNOLOGY RES AG 
Galarza, Jose M. 4 AMERICAN CYANAMID CO | WYETH HOLDINGS CORP | 
TECHNOVAX INC 
Kemble, George 4 MEDIMMUNE INC 
Larionova, Natalja 
Valentinovna 
4 AS SIBE MED EXPERIMENTAL MED RES INST 
Medvedeva, Tamilla E 4 AMS EXP MED RES INS | INFLUENZA RES INST | MED BIOLK 
PREP STANDARD | MOSC VIRUS PREPD RES INST 
Nabel, Gary J. 4 US DEPT HEALTH&HUMAN SERVICES 
Ohkuma, Kunio 4 CHEMO SERO THERAPEUTIC RES INS |NAT INST OF HEALTH 
JAPAN 
Osterhaus, Albert D.M.E. 4 ABBOTT BIOLOGICALS BV | SOLVAY BIOLOGICALS BV | UNIV 
ROTTERDAM ERASMUS CENT MEDICAL 
Wei, Chih-Jen 4 US DEPT HEALTH&HUMAN SERVICES 
Wolschek, Markus 4 AVIR GREEN HILLS BIOTECHNOLOGY RES AG  
Yang, Chin-Fen 4 MEDIMMUNE INC  
Yang, Zhi-Yong 4 US DEPT HEALTH&HUMAN SERVICES 
 
The same analysis was performed with supporting technologies documents, as shown in Table 
VI.  There were more inventors (47) with four or more patent families, but number of patent 
documents per inventor was lower than that with the vaccine documents.  For example, G.I. 
Aleksandrova was the top inventor on both lists, but this inventor had 27 patents documents in 
the vaccines category but only 15 in the supporting technologies category.  Overall, this agrees 
with the previous determination that the supporting technologies category represents a more 
diverse pool of documents than the documents in the vaccines category.  Many of the vaccine 
inventors also appear on the supporting technologies list, which was probably to be expected. 
The assignees associated with these inventors are surprisingly different from the vaccine 
inventors list.  GSK is represented on the supporting technologies list of inventors but Pfizer and 
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Merck are not.  Non-profit entities are more represented, with 34 of the 47 inventors working for 
such institutions.  Russian and Chinese inventors were prominent on the top of the supporting 
technologies inventor list.  A prominent person on this list is Dr. Peter Palese,
140
 of Mount Sinai 
School of Medicine in New York, USA.  Dr. Palese uses reverse genetics as a tool to modify and 
study pandemic influenza strains.
141
   
 
Complete inventor data for the supporting technologies category are given in Appendix I. 
 
 





Assignee - DWPI 
Aleksandrova,  Galina 
Ibragimovna 
15 A MED EXPER MED RES INST 
Kawaoka, Yoshihiro 15 ST JUDE CHILDREN'S RES HOSPITAL | US DEPT 
HEALTH & HUMAN SERVICES 
Rudenko, Larisa 
Georgievna 
14 A MED EXPER MED RES INST 
Klimov, Aleksandr I 11 A MED EXPER MED RES INST 
Chen, Hua-lan 10 CHINESE ACAD AGRIC SCI HARBIN VETERINARY 
MEDICINE INST 
Smith, Gail Eugene 9 MG-PMC LLC | MICROGENESYS INC | PROTEIN SCI 
CORP 




8 NIZHEGOROD EPIDEMICS MICROBIOLOG INST | 
VEKTOR VIROLOGY & BIOTECH RES CENTRE 
Palese, Peter M. 8 MOUNT SINAI SCHOOL MEDICINE 
Webster, Robert G. 8 ST JUDE CHILDREN'S RES HOSPITAL 
Garcia-Sastre, Adolfo 7 ISIS INNOVATION LTD | UNIV NEW YORK MT SINAI 
SCHOOL MEDICINE  
Polezhaev, Fial I 7  
Yoon, In Joong 7 CHOONG ANG VACCINE LAB | VACCINE LEADER 
LI, Ying-bo 6 CHINESE ACAD SCI KUNMING INST ZOOLOGY 
Seo, Sang Heui 6 CHOONG ANG VACCINE LAB | VACCINE LEADER 
Chen, Qin-qin 5 CHINESE ACAD SCI KUNMING INST ZOOLOGY 
LI, Hui 5  
Neumann, Gabriele 5 WISCONSIN ALUMNI RES FOUND 
Shin, Yeun-Kyung 5 REPUBLIC KOREA MANAGEMENT MIN AGRIC&FI 
                                                 
140
 See e.g. http://www.mountsinai.org/profiles/peter-palese.  
141
 See e.g. http://www.sciencemag.org/content/310/5745/77.short.  
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Song, Jae Young 5 REPUBLIC KOREA MANAGEMENT MIN AGRIC&FI | 
UNIV CHUNGBUK NAT IND ACAD COOP FOUND 
Akopova, Irina Ivanovna 4 NIZHEGOROD EPIDEMICS MICROBIOLOG INST | 
VEKTOR VIROLOGY & BIOTECH RES CENTRE 
Andre, Bruno, Rene 4 GLAXOSMITHKLINE  
Audonnet, Jean-
Christophe Francis 
4 MERIAL | MERIAL SAS | RHONE MERIEUX SA 
Cao, Yong-chang 4 UNIV SUN YET-SEN 
Champluvier, Benoit Paul 
Suzanne 
4 GLAXOSMITHKLINE  
Choi, Young Ki 4 REPUBLIC KOREA MANAGEMENT MIN AGRIC&FI | 
UNIV CHUNGBUK NAT IND ACAD COOP FOUND 
Couture, Manon 4 MEDICAGO INC 
Egorov, Andrej 4 A MED EXPER MED RES INST 
Garmashova, Lyudmila M 4  
Gou, Hong-ying 4 LIAONING TIANCHENG INST BIOLOGICAL MEDIC | 
TIANCHENG INST BIOLOGICAL PHARMACY LIAON 
Jiang, Yong-ping 4 HARBIN VETERINARY RES INST CAAS 
Jin, Hong 4 MEDIMMUNE LLC | MEDIMMUNE VACCINES INC 
Kim, Hyun Soo 4 CHOONG ANG VACCINE LAB | VACCINE LEADER 
Kwon, Hyuk Il 4 REPUBLIC KOREA MANAGEMENT MIN AGRIC&FI | 
UNIV CHUNGBUK NAT IND ACAD COOP FOUND 
Larionova, Natalja 
Valentinovna 
4 A MED EXPER MEDICINE RES INST 
Liu, Da-cai 4 UNIV SUN YET-SEN 
Markushin, Stanislav 
Georgievich 
4 NIZHEGOROD EPIDEMICS MICROBIOLOG INST | 
VEKTOR VIROLOGY & BIOTECH RES CENTRE 
Medvedeva, Tamilla E 4  
Murphy, Brian R. 4 ST JUDE CHILDREN'S RES HOSPITAL 
O'Hagan, Derek 4 CHIRON CORP | NOVARTIS VACCINES & 
DIAGNOSTICS INC 
Pushko, Peter M. 4 NOVAVAX INC  
Song, Min Suk 4 REPUBLIC KOREA MANAGEMENT MIN AGRIC&FI | 
UNIV CHUNGBUK NAT IND ACAD COOP FOUND 
Vezina, Louis-Philippe 4 MEDICAGO INC 
Wang, Cheng-yu 4 LIAONING TIANCHENG INST BIOLOGICAL MEDIC | 
TIANCHENG INST BIOLOGICAL PHARMACY LIAON 
Xue, Chun-yi 4 UNIV SUN YET-SEN 
Yoon, So Ra 4 REPUBLIC KOREA MANAGEMENT MIN AGRIC&FI | 
UNIV CHUNGBUK NAT IND ACAD COOP FOUND 
Yoon, Soon Seek 4 REPUBLIC KOREA MANAGEMENT MIN AGRIC&FI | 




Publication Year v. Patent Document Count 
 
Trends in publication of patent documents were analyzed for the two major categories.  
Publication date was chosen as the parameter for analysis, which indicates publication of 
applications generally 18 months after filing and publication of patents after allowance.  In the 
few cases in which the publication date was not recorded, the year of publication could usually 
be found in DWPI data such as the DWPI update information. 
 
 
Figure 16.  Publication trends for patent families in the influenza vaccine category.  The year of 
publication of each representative document of the 570 families is shown. 
 
The earliest representative family member in the vaccine category was a U.S. patent issued in 
1948, as shown in Figure 15.  The second place document was published 16 years later in 1964.  
From the mid 1960s until the mid 1990s, only one or two patents were published, on average.  In 
1997, the average number of publications leapt to 10, possibly because the TRIPS Agreement 
took effect in 1996 and patent applications began to be published 18 months after filing.  In 
2006, the number of influenza vaccine-related publications began to steadily climb, up to 104 in 
2011.  The number of publications in 2012 was approximately equal to that peak, especially 
considering this report includes a thorough search of patent only up to early October 2012, and 
thus the search did not cover the entire calendar year.   
 
The increase in filing of patent applications also correlates with the H5N1 (bird flu) epidemic 






























The data may be somewhat skewed because the representative family member was chosen as the 
latest publication from the U.S., or the latest document from another jurisdiction if there was no 
U.S. family member.  However, the trend still indicates an increased interest in influenza vaccine 
technologies in the last case. 
 
Supporting technology publication trends present a similar story, as shown in Figure 16.  Only 
three such documents were published before 1966.  In the 1970s, there was a higher average 
level of patent publication than that for vaccine patents, but this average dropped to only two 
documents per year in the late 1980s and early 1990s.  There was a small increase when 
applications began to be published.  However, since at least 2004 there has been a steady 
increase in publication of supporting technology documents.  In fact, even though the data is not 
complete 2012, there were still 151 publications in that partial year, which represents a 
substantial increase over the 102 publications in 2011.  Again, this increase in patent filings is 
likely driven by a response to the 1997 H5N1 epidemic and the 2009 H1N1 pandemic. 
 
 
Figure 17.  Publication trends for patent families in the supporting technologies category.  The 































Supporting Technologies Patent Publications by Year 
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U.S. Classification by Patent Document Count 
 
Every patent application submitted to the U.S.P.T.O. receives a preliminary classification which 
determines the art unit in which that application is examined.  The patent examiner assigns other 
classes to the application as she feels appropriate to indicate the technologies important the 
particular invention disclosed by the application.  The U.S. Patent Classification System (USPC)  
“ is a system for organizing all U.S. patent documents and many other technical documents into 
relatively small collections based on common subject matter.”142  The USPC groups similar 
patent documents together into small classes which can be searched.  For example, once a 
relevant document is identified, an interested person could search the U.S. class of that document 
for other relevant references.  This represents an alternative to keyword searching for relevant 
documents, and this system may help identify relevant documents when specific keywords are 
difficult to ascertain.  Certainly, class searching should supplement any keyword search to ensure 
all relevant documents are identified. 
 
The U.S.P.T.O. is currently revising its classification system to bring the USPC into harmony 
with the European Classification System (ECLA) to facilitate identification of relevant 
documents from multiple jurisdictions.
143
  While the USPC is being revised, it is useful to 
present an analysis of the current USPC since complete harmonization has not been achieved to 
date. 
 
Figure 17 shows the 53 different classes that have been assigned to influenza vaccine documents 
by the U.S.P.T.O.  Most documents were assigned to Class 424, particularly the subclasses 
209.1, 210.1, 206.1, and 186.1.  The definitions for each of the top classes are given in Table 
VII.  Class 424 is related to vaccines, and subclasses 209.1, 206.1, and 210.1 are specifically 
limited to influenza vaccines.  Class 424/450 is directed to liposomes as carriers in vaccines.  
Classes 514/044R and 435/320.1 are directed to DNA sequences, probably as used in DNA 
vaccines or in the production of recombinant viruses and subunits. 
 
As indicated before, the supporting technologies category contains a broader range of inventions 
so there are 74 different classes assigned to documents in this category, as shown in Figure 18.  
Many of the top classes are the same between the two categories, including the number one class 
on both lists, 424/209.1.  The list of top classes for supporting technologies did have three 
classes that were not prominent with vaccine documents.  Class 435/239 contains technologies 
related to virus purification, which would describe the subcategory of methods of making 
vaccines.  Additionally, Classes 435/069.3 and 435/069.1 contains recombinant peptides, which 
could include novel subunits useful in vaccines.  Table VIII lists the definitions of these classes. 
 
                                                 
142
 http://www.uspto.gov/patents/resources/classification/overview.pdf.  
143


































































Vaccines: Main U.S. Class per INPADOC Family 
Figure 18.  USPC classes assigned 
to influenza vaccine documents. 
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Table VII.  Top U.S. Classes for Vaccine Documents. 
US Class - 
Main 
# Docs Class Title 
424/209.1 45 ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G., 
IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELL-
DIATED IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC 
IMMUNOSUPPRESSOR, ETC. (184.1): Virus or component thereof (204.1):  
Orthomyxoviridae (e.g., influenza virus, fowl plague virus, etc.) 
424/206.1 32 ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G., 
IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELL-
DIATED IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC 
IMMUNOSUPPRESSOR, ETC. (184.1): Virus or component thereof (204.1):  
Reassortant or deletion mutant virus (205.1):  Influenza virus 
424/186.1 23 ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G., 
IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELL-
DIATED IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC 
IMMUNOSUPPRESSOR, ETC. (184.1): Amino acid sequence disclosed in whole 
or in part; or conjugate, complex, or fusion protein or fusion polypeptide 
including the same (185.1): Disclosed amino acid sequence derived from 
virus 
424/210.1 18 ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G., 
IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELL-
DIATED IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC 
IMMUNOSUPPRESSOR, ETC. (184.1): Virus or component thereof (204.1):   
Orthomyxoviridae (209.1):  Subunit vaccine containing hemagglutinin or 
neuraminidase 
424/450 10 PREPARATIONS CHARACTERIZED BY SPECIAL PHYSICAL FORM (400):   
Liposomes 
424/199.1 9 ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G., 
IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELL-
DIATED IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC 
IMMUNOSUPPRESSOR, ETC. (184.1):  Recombinant virus encoding one or 
more heterologous proteins or fragments thereof 
424/192.1 7 ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G., 
IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELL-
DIATED IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC 
IMMUNOSUPPRESSOR, ETC. (184.1):  Fusion protein or fusion polypeptide 
(i.e., expression product of gene fusion) 
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424/202.1 6 ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G., 
IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELL-
DIATED IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC 
IMMUNOSUPPRESSOR, ETC. (184.1):  Combination of antigens from multiple 
viral species (e.g., multivalent viral vaccine, etc.) 
514/044R 6 DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI) (001): 
Carbohydrate (i.e., saccharide radical containing) DOAI (023): N-glycoside 
(042): Nitrogen containing hetero ring (043): Polynucleotide (e.g., RNA, DNA, 
etc.) 
424/204.1 5 ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G., 
IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELL-
DIATED IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC 
IMMUNOSUPPRESSOR, ETC. (184.1): Virus or component thereof 
435/235.1 5 VIRUS OR BACTERIOPHAGE, EXCEPT FOR VIRAL VECTOR OR BACTERIOPHAGE 
VECTOR; COMPOSITION THEREOF; PREPARATION OR PURIFICATION 
THEREOF; PRODUCTION OF VIRAL SUBUNITS; MEDIA FOR PROPAGATING 
435/005 4 MEASURING OR TESTING PROCESS INVOLVING ENZYMES OR MICRO-
ORGANISMS; COMPOSITION OR TEST STRIP THEREFORE; PROCESSES OF 
FORMING SUCH COMPOSITION OR TEST STRIP (004):  Involving virus or 
bacteriophage  
424/185.1 4 ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G., 
IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELL-
DIATED IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC 
IMMUNOSUPPRESSOR, ETC. (184.1): Amino acid sequence disclosed in whole 
or in part; or conjugate, complex, or fusion protein or fusion polypeptide 
including the same 
435/320.1 4 VECTOR, PER SE (E.G., PLASMID, HYBRID PLASMID, COSMID, VIRAL VECTOR, 
























































































Supporting Technologies - Main U.S. Class 
Figure 19.  USPC classes assigned 




Table VIII.  Top U.S. Classes for Supporting Technology Documents. 
US Class - 
Main 
# Docs Class Title 
424/209.1 50 ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G., 
IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELL-DIATED 
IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC 
IMMUNOSUPPRESSOR, ETC. (184.1): Virus or component thereof (204.1):  
Orthomyxoviridae (e.g., influenza virus, fowl plague virus, etc.) 
424/210.1 15 ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G., 
IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELL-DIATED 
IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC 
IMMUNOSUPPRESSOR, ETC. (184.1): Virus or component thereof (204.1):   
Orthomyxoviridae (209.1):  Subunit vaccine containing hemagglutinin or 
neuraminidase 
435/239 14 VIRUS OR BACTERIOPHAGE, EXCEPT FOR VIRAL VECTOR OR BACTERIOPHAGE 
VECTOR; COMPOSITION THEREOF; PREPARATION OR PURIFICATION 
THEREOF; PRODUCTION OF VIRAL SUBUNITS; MEDIA FOR PROPAGATING 
(235.1): Recovery or purification 
424/199.1 13 ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G., 
IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELL-DIATED 
IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC 
IMMUNOSUPPRESSOR, ETC. (184.1):  Recombinant virus encoding one or 
more heterologous proteins or fragments thereof 
424/206.1 12 ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G., 
IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELL-DIATED 
IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC 
IMMUNOSUPPRESSOR, ETC. (184.1): Virus or component thereof (204.1):  
Reassortant or deletion mutant virus (205.1):  Influenza virus 
424/204.1 11 ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G., 
IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELL-DIATED 
IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC 
IMMUNOSUPPRESSOR, ETC. (184.1): Virus or component thereof 
435/235.1 9 VIRUS OR BACTERIOPHAGE, EXCEPT FOR VIRAL VECTOR OR BACTERIOPHAGE 
VECTOR; COMPOSITION THEREOF; PREPARATION OR PURIFICATION 
THEREOF; PRODUCTION OF VIRAL SUBUNITS; MEDIA FOR PROPAGATING 
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424/186.1 9 ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G., 
IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELL-DIATED 
IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC 
IMMUNOSUPPRESSOR, ETC. (184.1): Amino acid sequence disclosed in whole 
or in part; or conjugate, complex, or fusion protein or fusion polypeptide 
including the same (185.1): Disclosed amino acid sequence derived from virus 
435/005 7 MEASURING OR TESTING PROCESS INVOLVING ENZYMES OR MICRO-
ORGANISMS; COMPOSITION OR TEST STRIP THEREFORE; PROCESSES OF 
FORMING SUCH COMPOSITION OR TEST STRIP (004):  Involving virus or 
bacteriophage  
435/069.3 4 
MICROORGANISM, TISSUE CELL CULTURE, OR ENZYME USING PROCESS TO 
SYNTHESIZE A DESIRED CHEMICAL COMPOUND OR COMPOSITION (41): 
 Recombinant DNA technique included in method of making a protein or 
polypeptide  (69.1): Antigens 
435/069.1 4 MICROORGANISM, TISSUE CELL CULTURE, OR ENZYME USING PROCESS TO 
SYNTHESIZE A DESIRED CHEMICAL COMPOUND OR COMPOSITION (41):  
Recombinant DNA technique included in method of making a protein or 
polypeptide 
424/450 4  Recombinant DNA technique included in method of making a protein or 
polypeptide   
 
 
Top IPC (Current) Classifications 
 
The International Patent Classification (IPC) system, established in 1971, is administrated by the 
World Intellectual Property Organization (WIPO).  The IPC “provides for a hierarchical system 
of language independent symbols for the classification of patents and utility models according to 
the different areas of technology to which they pertain.”144  The IPC contains eight core sections 
with approximately 70,000 subdivisions, called advanced levels.  WIPO continuously revises the 
IPC, with the core levels being updated every three years and the advance levels being reviewed 
a few times each year.  The current version of the core levels was released in 2012.   
 
The IPC (Current) codes were analyzed for each patent family.  Some families had more than 
one code, and each was counted.  For the vaccine category, 15 codes represented more than 20 
families each, as shown in Figure 19.  The two classes that represented the most families were 
A61K 39/145, which contains preparations of influenza antigens such as a vaccine, and A61P 
31/16, which contains pharmaceutical compositions used to treat influenza infections. The 
definitions of the top IPC classes for vaccine documents are given in Table IX. 
                                                 
144
 World Intellectual Property Organization, Preface to the International Patent Classification (IPC), WIPO IP 





Figure 20.  Top IPC (Current) Classification of Vaccine Families.  Each class represented at least 
21 different families. 
 
Table IX. Definitions of the Top IPC (Current) Classifications of Vaccine Documents. 
IPC - Current # Docs Class Description 
A61K 39/00 55 MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Medicinal preparations 
containing antigens or antibodies 
A61K 39/12 34 MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Medicinal preparations 
containing antigens or antibodies (A61K 39/00): Viral antigens 
A61K 39/145 297 MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Medicinal preparations 
containing antigens or antibodies (A61K 39/00): Viral antigens (39/12):  
Orthomyxoviridae, e.g. influenza virus 
A61K 39/295 25 MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Medicinal preparations 
containing antigens or antibodies (A61K 39/00): Viral antigens (39/12): 
Polyvalent viral antigens; Mixtures of viral and bacterial antigens 
A61K 39/39 47 MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Medicinal preparations 
containing antigens or antibodies (A61K 39/00): characterised by the 
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A61K 48/00 29 MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Medicinal preparations 
containing genetic material which is inserted into cells of the living body to 
treat genetic diseases; Gene therapy 
A61P 31/12 22 MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Antiinfectives, i.e. 
antibiotics, antiseptics, chemotherapeutics (A61P 31/00): Antivirals 
A61P 31/16 158 MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Antiinfectives, i.e. 
antibiotics, antiseptics, chemotherapeutics (A61P 31/00): Antivirals (31/12):  
for RNA viruses (31/14): for influenza or rhinoviruses 
A61P 37/04 59 MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Drugs for immunological 
or allergic disorders (A61P 37/00): Immunomodulators (37/02): 
Immunostimulants 
C07K 14/11 68 ORGANIC CHEMISTRY (C07): Peptides having more than 20 amino acids; 
Gastrins; Somatostatins; Melanotropins; Derivatives thereof (C07K 14/00): 
from viruses (14/005): RNA viruses (14/08): Orthomyxoviridae, e.g. influenza 
virus 
C12N 07/00 59 BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; 
ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING (C12): Viruses, e.g. 
bacteriophages; Compositions thereof; Preparation or purification thereof 
C12N 07/01 34 BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; 
ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING (C12): Viruses, e.g. 
bacteriophages; Compositions thereof; Preparation or purification thereof 
(C12N 07/00): Viruses, e.g. bacteriophages, modified by introduction of 
foreign genetic material 
C12N 07/04 30 BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; 
ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING (C12): Viruses, e.g. 
bacteriophages; Compositions thereof; Preparation or purification thereof 
(C12N 07/00): Inactivation or attenuation; Producing viral sub-units 
C12N 15/44 25 BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; 
ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING (C12): Mutation or 
genetic engineering; DNA or RNA concerning genetic engineering, vectors, 
e.g. plasmids, or their isolation, preparation or purification; Use of hosts 
therefor (C12N 15/00): Recombinant DNA-technology (15/09): DNA or RNA 
fragments; Modified forms thereof (15/11): Genes encoding microbial 
proteins, e.g. enterotoxins (15/31): Genes encoding viral proteins (15/33): 




C12N 15/63 21 BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; 
ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING (C12): Mutation or 
genetic engineering; DNA or RNA concerning genetic engineering, vectors, 
e.g. plasmids, or their isolation, preparation or purification; Use of hosts 
therefor (C12N 15/00): Recombinant DNA-technology (15/09): Introduction 
of foreign genetic material using vectors; Vectors; Use of hosts therefor; 
Regulation of expression 
 
 
Again, the supporting technologies category had a broader spectrum of top classes, with 20 
different classes each representing at least 21 families, as shown in Figure 20.  However, the top 
two classes, A61k 39/145 and A61P 31/16, were the same as with the vaccine category.  Two of 
the five additional classifications, C12N 15/09 and A61P 31/14 were merely higher level 
classifications of previously identified, more narrow classes.  The three new classes were C12N 
05/10, which concerns culture of transformed cell lines such as for the production of viruses or 
viral subunits, C12N 07/02, which concerns methods of purifying viruses, and C12N 15/86, 
which concerns DNA constructs such as for producing recombinant polypeptides.  Complete 
definitions are located in Table X. 
 
 
Figure 21. Top IPC (Current) Classification of Supporting Technology Documents.  Each class 
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Table X. Definitions of the Top IPC (Current) Classifications of Supporting Technology 
Documents. 
IPC - Current # Docs Class Definitions 
A61K 39/00 69 MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Medicinal 
preparations containing antigens or antibodies 
A61K 39/12 85 MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Medicinal 
preparations containing antigens or antibodies (A61K 39/00): Viral 
antigens 
A61K 39/145 362 MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Medicinal 
preparations containing antigens or antibodies (A61K 39/00): Viral 
antigens (39/12):  Orthomyxoviridae, e.g. influenza virus 
A61K 39/295 37 MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Medicinal 
preparations containing antigens or antibodies (A61K 39/00): Viral 
antigens (39/12): Polyvalent viral antigens; Mixtures of viral and 
bacterial antigens 
A61K 39/39 26 MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Medicinal 
preparations containing antigens or antibodies (A61K 39/00): 
characterised by the immunostimulating additives, e.g. chemical 
adjuvants 
A61K 48/00 29 MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Medicinal 
preparations containing genetic material which is inserted into 
cells of the living body to treat genetic diseases; Gene therapy 
A61P 31/12 41 MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Antiinfectives, 
i.e. antibiotics, antiseptics, chemotherapeutics (A61P 31/00): 
Antivirals 
A61P 31/14 22 MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Antiinfectives, 
i.e. antibiotics, antiseptics, chemotherapeutics (A61P 31/00): 
Antivirals (31/12):  for RNA viruses 
A61P 31/16 169 MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Antiinfectives, 
i.e. antibiotics, antiseptics, chemotherapeutics (A61P 31/00): 
Antivirals (31/12):  for RNA viruses (31/14): for influenza or 
rhinoviruses 
A61P 37/04 48 MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Drugs for 
immunological or allergic disorders (A61P 37/00): 
Immunomodulators (37/02): Immunostimulants 
C07K 14/11 87 ORGANIC CHEMISTRY (C07): Peptides having more than 20 amino 
acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof 
(C07K 14/00): from viruses (14/005): RNA viruses (14/08): 
Orthomyxoviridae, e.g. influenza virus 
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C12N 05/10 33 BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; 
ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING (C12): 
Undifferentiated human, animal or plant cells, e.g. cell lines; 
Tissues; Cultivation or maintenance thereof; Culture media 
therefor (C12N 5/00): Cells modified by introduction of foreign 
genetic material, e.g. virus-transformed cells 
C12N 07/00 115 BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; 
ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING (C12): 
Viruses, e.g. bacteriophages; Compositions thereof; Preparation or 
purification thereof 
C12N 07/01 63 BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; 
ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING (C12): 
Viruses, e.g. bacteriophages; Compositions thereof; Preparation or 
purification thereof (C12N 07/00): Viruses, e.g. bacteriophages, 
modified by introduction of foreign genetic material 
C12N 07/02 65 BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; 
ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING (C12): 
Viruses, e.g. bacteriophages; Compositions thereof; Preparation or 
purification thereof (C12N 07/00): Recovery or purification 
C12N 07/04 53 BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; 
ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING (C12): 
Viruses, e.g. bacteriophages; Compositions thereof; Preparation or 
purification thereof (C12N 07/00): Inactivation or attenuation; 
Producing viral sub-units 
C12N 15/09 34 BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; 
ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING (C12): 
Mutation or genetic engineering; DNA or RNA concerning genetic 
engineering, vectors, e.g. plasmids, or their isolation, preparation 
or purification; Use of hosts therefor (C12N 15/00): Recombinant 
DNA-technology 
C12N 15/44 40 BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; 
ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING (C12): 
Mutation or genetic engineering; DNA or RNA concerning genetic 
engineering, vectors, e.g. plasmids, or their isolation, preparation 
or purification; Use of hosts therefor (C12N 15/00): Recombinant 
DNA-technology (15/09): DNA or RNA fragments; Modified forms 
thereof (15/11): Genes encoding microbial proteins, e.g. 
enterotoxins (15/31): Genes encoding viral proteins (15/33): 
Proteins from RNA viruses, e.g. flaviviruses (15/40): 
Orthomyxoviridae, e.g. influenza virus 
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C12N 15/63 23 BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; 
ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING (C12): 
Mutation or genetic engineering; DNA or RNA concerning genetic 
engineering, vectors, e.g. plasmids, or their isolation, preparation 
or purification; Use of hosts therefor (C12N 15/00): Recombinant 
DNA-technology (15/09): Introduction of foreign genetic material 
using vectors; Vectors; Use of hosts therefor; Regulation of 
expression 
C12N 15/86 27 BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; 
ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING (C12): 
Mutation or genetic engineering; DNA or RNA concerning genetic 
engineering, vectors, e.g. plasmids, or their isolation, preparation 
or purification; Use of hosts therefor (C12N 15/00): Recombinant 
DNA-technology (15/09): DNA or RNA fragments; Modified forms 
thereof (15/11):  Vectors or expression systems specially adapted 
for eukaryotic hosts (15/79): for animal cells (15/85): Viral vectors 
 
 
Top DWPI Classification v. Patent Document Count 
 
The DWPI classification system uses a simple way of categorizing patent documents.  This 
system was developed by Thomson Scientific to facilitate searching of a particular area of a 
given technology by providing a smaller initial pool of documents to search.  As per this system, 
patents are broadly divided into three areas: Chemical, Engineering, and Electronic and 
Electrical Engineering.  Each of these is then further divided into Sections and Classes which 
describe the technical area, or areas, covered by the patent. 
 
The pattern of top DWPI codes was similar for the vaccine category and the supporting 
technologies category, as shown in Figure 21.  Among codes representing at least 10 families 
each, the top three codes for both categories was B04, which covers polymers such as 
polypeptides, D16, which covers cultures of cell lines or yeast, and C06, which covers 
production of recombinant proteins in plants and veterinary vaccines.  Full definitions of the 
codes are given in Table XI. 
 
There were only minor differences between the two categories, perhaps because the DWPI codes 
represent fairly broad areas of technology and cannot distinguish among the various categories 




Figure 22.  Top DWPI Classes for Both Vaccines and Supporting Technology Documents. 
 






A96 55 81 Polymers and Plastics: Medical, dental, veterinary, cosmetic 
B00 0 16 Pharmaceuticals 
B03 0 10 Pharmaceuticals: Other heterocyclics 
B04 534 671 Pharmaceuticals: Natural products and polymers. Including testing 
of body fluids (other than blood typing or cell counting), 
pharmaceuticals or veterinary compounds of unknown structure, 
testing of microorganisms for pathogenicity, testing of chemicals 
for mutagenicity or human toxicity and fermentative production of 
DNA or RNA. General compositions. 
B05 13 13 Pharmaceuticals: Other organics - aromatics, aliphatic, organo-
metallics, compounds whose substituents vary such that they 
would be classified in several of B01 - B05. 
B07 37 26 Pharmaceuticals: General - tablets, dispensers, catheters (excluding 
drainage and angioplasty), encapsulation etc, but not systems for 
administration of blood or saline or IV feeding etc. 
C03 
0 34 Agricultural Chemicals: Other organic compounds, inorganic 
compounds and multi-component mixtures. Polymers and proteins. 




















































D16  517 640 Food, Detergents, Water Treatment and Biotechnology: 
Fermentation industry - including fermentation equipment, 
brewing, yeast production, production of pharmaceuticals and 
other chemicals by fermentation, microbiology, production of 
vaccines and antibodies, cell and tissue culture and genetic 
engineering. 
P34  10 0 General Engineering: HEALTH, AMUSEMENT: Sterilising, syringes, 
electrotherapy 
S03 15 29 Instrumentation, Measuring and Testing: Scientific Instrumentation 
(G01J, K, N, T-W) Photometry, calorimetry. Thermometers. 
Meteorology, geophysics, measurement of nuclear or X-radiation. 
Investigating chemical or physical properties. 
T01 10 0 Computing and Control: Digital Computers (G06C-F) Electronic data 
processors, interfaces and programme control. Mechanical digital 
computers. 
 
Top Derwent Manual Codes v. Patent Document Count  
 
The Derwent Manual Code represents a further level of classification that provides more 
specificity to the DWPI Codes.
145
  Again, patent families often had multiple different Manual 
Code associated with them, and each code was taken for analysis.  Among vaccine documents, 
24 different Manual Codes each represented more than 50 INPADOC families, as shown in 
Figure 22.  The top three codes were D05-H07, which concerns production of vaccines, B14-
S11D3, which concerns genetically engineered vaccines, and B14-A02B2, which concerns 
orthomyxoviruses.  The definition of top Manual Codes are given in Table XII. 
 
Once again, the supporting technologies category was covered by more Manual Codes than the 
vaccine category was.  Thirty-six different Manual Codes were applied to 50 or more INPADOC 
families, as shown in Figure 23.  D05-H07 and B14-A02B2 were again among the top three 
codes, but the second most prominent code for the supporting technologies was B14-S11A, 
which concerns antiviral vaccines.  Additional Manual Codes appearing in association with 
supporting technology documents was B04-F0100E, D05-H08, and D05-H14, which all concern 
transformed cell lines such as those used to produce recombinant viruses or subunits, and B14-
S12, which concerns veterinary pharmaceuticals such as vaccines.  In general the supporting 
technologies documents had more Manual Codes in the C04 and C14 classes, which cover 
veterinary uses of pharmaceuticals.  Thus, the differences in the Manual Codes represent the 
different subcategories under the vaccine and supporting technology headings. 
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Figure 23. Top Derwent Manual Codes representing at least 50 vaccine documents. 
 




# Docs. Code Description 
D05-H12F 68 Food, Detergents, Water Treatment and Biotechnology: RECOMBINANT 
VIRUSES [EXCLUDING VIRAL VECTORS] 
D05-H12E 111 Food, Detergents, Water Treatment and Biotechnology: VECTORS 
D05-H12A 70 Food, Detergents, Water Treatment and Biotechnology: WILD-TYPE CODING 
SEQUENCES 
D05-H07 446 Food, Detergents, Water Treatment and Biotechnology: PRODUCTION OF 
VACCINES, ANTIGENS 
C14-S11A 130 Agricultural Chemicals: ANTIVIRAL VACCINE 
C14-G01 62 Agricultural Chemicals: IMMUNOSTIMULANT GENERAL AND OTHER 
C14-A02B2 95 Agricultural Chemicals: (PARA/ORTHO)MYXOVIRUS 
C04-B04C1 50 Agricultural Chemicals: MICROBIAL ANTIGEN 
B14-S11D3 112 Pharmaceuticals: SYNTHETIC/GENETICALLY ENGINEERED VACCINE 
B14-S11D2 60 Pharmaceuticals: LIVE-ATTENUATED (WEAKENED) VACCINE 
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B14-S11A 415 Pharmaceuticals: ANTIVIRAL VACCINE 
B14-S11 52 Pharmaceuticals: VACCINE [GENERAL] 
B14-G01 181 Pharmaceuticals: IMMUNOSTIMULANT GENERAL AND OTHER 
B14-A02B2 322 Pharmaceuticals: (PARA/ORTHO)MYXOVIRUS 
B14-A02 60 Pharmaceuticals: ANTIVIRAL [GENERAL] 
B04-N03 69 Pharmaceuticals: MICROORGANISM PROTEIN/POLYPEPTIDE (NO SEQUENCE) 
B04-
F11B0E 
52 Pharmaceuticals: RNA VIRUS GENERAL (GENETICALLY ENGINEERED) 
B04-F11B 80 Pharmaceuticals: RNA VIRUS GENERAL 
B04-
F1100E 
51 Pharmaceuticals: VIRUSES (GENETICALLY ENGINEERED) 
B04-F11 53 Pharmaceuticals: VIRUSES 
B04-E99 68 Pharmaceuticals: PATENT WITH GENESEQ RECORD 
B04-E08 125 Pharmaceuticals: VECTORS, PLASMIDS, COSMIDS, TRANSPOSONS 
B04-B04C1 172 Pharmaceuticals: MICROBIAL ANTIGEN 



































































Table XIII.  Definitions of Top Derwent Manual Codes for Supporting Technology Documents. 
DWPI Manual 
Codes 
# Docs Code Description 
D05-H14 71 Food, Detergents, Water Treatment and Biotechnology: RECOMBINANT 
CELLS 
D05-H12F 107 Food, Detergents, Water Treatment and Biotechnology: RECOMBINANT 
VIRUSES [EXCLUDING VIRAL VECTORS] 
D05-H12E 134 Food, Detergents, Water Treatment and Biotechnology: VECTORS 
D05-H12A 73 Food, Detergents, Water Treatment and Biotechnology: WILD-TYPE 
CODING SEQUENCES 
D05-H08 65 Food, Detergents, Water Treatment and Biotechnology: CELL OR TISSUE 
CULTURE 
D05-H07 532 Food, Detergents, Water Treatment and Biotechnology: PRODUCTION OF 
VACCINES, ANTIGENS 
D05-H06A 55 Food, Detergents, Water Treatment and Biotechnology: NEWLY 
DISCOVERED, TESTING OF, ISOLATION OF, IDENTIFICATION OF AND 
DETECTION OF VIRUSES 
D05-H06 52 Food, Detergents, Water Treatment and Biotechnology: NEWLY 
DISCOVERED, TESTING OF, ISOLATION OF, IDENTIFICATION OF AND 
DETECTION OF VIRUSES AND OTHER 
C14-S12 76 Agricultural Chemicals: VETERINARY 
C14-S11D3 103 Agricultural Chemicals: SYNTHETIC/GENETICALLY ENGINEERED VACCINE 
C14-S11A 208 Agricultural Chemicals: ANTIVIRAL VACCINE 
C14-G01 67 Agricultural Chemicals: IMMUNOSTIMULANT GENERAL AND OTHER 
C14-A02B2 140 Agricultural Chemicals: (PARA/ORTHO)MYXOVIRUS 
C04-F11B0E 53 Agricultural Chemicals: RNA VIRUS GENERAL (GENETICALLY ENGINEERED) 
C04-F11B 53 Agricultural Chemicals: RNA VIRUS GENERAL 
C04-E99 50 Agricultural Chemicals: PATENT WITH GENESEQ RECORD 
C04-E08 66 Agricultural Chemicals: VECTORS, PLASMIDS, COSMIDS, TRANSPOSONS 
C04-B04C1 69 Agricultural Chemicals: MICROBIAL ANTIGEN 
B14-S12 84 Pharmaceuticals: VETERINARY 
B14-S11D3 163 Pharmaceuticals: SYNTHETIC/GENETICALLY ENGINEERED VACCINE 
B14-S11D2 72 Pharmaceuticals: LIVE-ATTENUATED (WEAKENED) VACCINE 
B14-S11D1 55 Pharmaceuticals: WHOLE-KILLED (INACTIVE) VACCINE 
B14-S11A 454 Pharmaceuticals: ANTIVIRAL VACCINE 
B14-G01 156 Pharmaceuticals: IMMUNOSTIMULANT GENERAL AND OTHER 
B14-A02B2 303 Pharmaceuticals: (PARA/ORTHO)MYXOVIRUS 
B14-A02 71 Pharmaceuticals: ANTIVIRAL [GENERAL] 
B04-F11B0E 98 Pharmaceuticals: RNA VIRUS GENERAL (GENETICALLY ENGINEERED) 
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B04-F11B 121 Pharmaceuticals: RNA VIRUS GENERAL 
B04-F1100E 64 Pharmaceuticals: VIRUSES (GENETICALLY ENGINEERED) 
B04-F11 89 Pharmaceuticals: VIRUSES 
B04-F0100E 74 Pharmaceuticals: CELLS, MICROORGANISMS, TRANSFORMANTS, HOSTS, 
CELL LINES, TISSUE [GENERAL] (GENETICALLY ENGINEERED) 
B04-E99 69 Pharmaceuticals: PATENT WITH GENESEQ RECORD 
B04-E08 149 Pharmaceuticals: VECTORS, PLASMIDS, COSMIDS, TRANSPOSONS 
B04-B04C1 130 Pharmaceuticals: MICROBIAL ANTIGEN 
B02-V 89 Pharmaceuticals: VACCINES AND ANTIBIOTICS BEGINNING WITH THE 
LETTER "V", GENERAL VACCINES 
















A search of the patent literature for publications containing keywords related to the influenza 
virus returned approximately 33,500 total documents representing almost 3,800 patent families.  
However, only about one-half of those patent documents will actually be specific for 
prophylactic influenza A vaccines or for technologies that are used in the manufacture of 
vaccines.  Of those relevant documents, approximately 10-15% are specifically related to 
pandemic influenza, although the remainder could probably be applied to pandemic strains.  
Thus, influenza vaccine technologies are disclosed in a fairly small set of patent documents, 
especially considering that influenza virus infections have been a global threat to human health 
for at least century.   
 
However, filing of applications related to influenza have been steadily increasing in the last 
decade, so there are many new technological advances that have yet to be fully tested in the 
clinic for effectiveness against influenza.  Much of the increase in filings is in response to recent 
influenza outbreaks: the H5N1 (bird flu) epidemic that began in 1997 and continued for a 
decade, and the H1N1 (swine flu) pandemic that was first diagnosed in 2009. 
 
Influenza virus technologies appear to originate from a small set of countries, mostly the United 
States, Great Britain, France, China, Japan, Korea, and Russia.  Protection for influenza vaccine 
intellectual property has been sought worldwide.  However, except for Brazil coverage in South 
America is quite minimal, and except for South Africa protection for these technologies is sparse 
in Africa. 
 
Top assignees for the relevant families were mostly large pharmaceutical companies, with the 
majority of patent families coming from Novartis, followed by GlaxoSmithKline, Pfizer, U.S. 
Merck (Merck, Sharpe, & Dohme), Sanofi, and AstraZeneca.  Governmental and nonprofit 
institutes in China, Japan, Russia, South Korea and the United States also are contributing 
heavily to influenza vaccine research.   
 
Progress is being made towards the development of an effective vaccine against pandemic 
influenza strains, but much work remains to be done, especially testing these novel vaccines in 
the clinic.  Additionally, this much-needed technology is not adequately distributed to the least-
developed nations.  Once a new pandemic strain arises, infections could rapidly spread over an 
extensive area, so more thorough global preparedness is needed to prevent the health crisis this 







APPENDIX A: Master Coding Spreadsheet (electronic version only). 
 
This Excel file describes coding of representative INPADOC family members, with notes on the 
basis of the coding decisions.  The first sheet is organized by publication number, and the second 
sheet shows the publication numbers which fell in each category.  The third sheet shows the 
consolidated major categories. 
 
 
APPENDIX B: Platform Technologies Documents: Full Records (electronic version only). 
 
This Excel file has detailed information of each relevant patent family in this category.  The full 
records, containing all available information extracted from Thomson Innovation, are given for 




APPENDIX C: Vaccine Documents: Full Records (electronic version only). 
 
This Excel file has detailed information of each relevant patent family in this category.  The full 
records, containing all available information extracted from Thomson Innovation, are given for 
each representative family member.  The first sheet has documents organized alphabetically by 
publication number.  Subsequent sheets show the data manipulations used to determine priority 
countries, publications by year, major classifications, and family size.  Analyses of assignees, 
inventors, and top multi-jurisdictional filers are shown in separate files, as given below. 
 
 
APPENDIX D: Supporting Technologies Documents: Full Records (electronic version 
only). 
 
This Excel file has detailed information of each relevant patent family in this category.  The full 
records, containing all available information extracted from Thomson Innovation, are given for 
each representative family member.  The first sheet has documents organized alphabetically by 
publication number.  Subsequent sheets show the data manipulations used to determine priority 
countries, publications by year, and major classifications.  Analyses of assignees and inventors 






APPENDIX E: Top Multi-Jurisdictional Filings Spreadsheet (electronic version only). 
 
This Excel file has representative family members ranked according the size (number of 
publications) of the INPADOC family each document represents.  The top 21 largest families are 
then analyzed based on the total number of jurisdictions in which each family has been filed.  
Data is assembled from INPADOC, DWPI and TotalPatent family data.  Note that this analysis 
was performed for vaccine documents only. 
 
APPENDIX F:  Assignees Analysis Spreadsheet (electronic version only). 
 
Assignee data for each representative family member was manually corrected to reflect changing 
company names or the acquisition of an assignee by another company.  This Excel file details 
assignee data first by publication number, and then assignees are shown by total number of 
families believed to be owned by that assignee.  Both vaccines and supporting technology 
documents were pooled together to generate an assignee list covering all highly relevant 
documents.  The website for each assignee is also given, if possible. 
 
Appendix G:  Alternative Assignee Names and Subsidiaries Spreadsheet (electronic version 
only). 
 
The names of assignee companies can often change, particularly following mergers and 
acquisitions.  This data has been manually assembled as much as possible, and this Excel file 
details the alternative names and subsidiaries under which a given assignee may appear. 
 
Appendix H: Vaccine Inventors Spreadsheet (electronic version only). 
 
This Excel file separates each representative family member by the individual inventors listed in 
the record.  The top inventors who are listed on the most patent publications are then given.  
Note that inventor names are often misspelled, have variable middle names, or have first and last 
names switched.  For those reasons, the accuracy of this data cannot be entirely assured. 
 
Appendix I: Supporting Technology Inventors Spreadsheet (electronic version only). 
 
This Excel file separates each representative family member by the individual inventors listed in 
the record.  The top inventors who are listed on the most patent publications are then given.  
Note that inventor names are often misspelled, have variable middle names, or have first and last 






Appendix J: PDF Files of Representative Patent Documents (electronic version only). 
 
This folder contains the pdf files for each representative family member, if available.  Subfolders 
are given for each of the Vaccine and Supporting Technologies categories, but not Platforms.  
Note that in a few instances a pdf file of the representative family member was not available.  
Thus these folders do not contain the complete number of representative documents. 
 
 
Appendix K: PDF Files of Selected Non-Patent Literature (electronic version only). 
 
This folder contains pdf files for selected non-patent literature relevant to prophylactic influenza 
A vaccines.  An extensive search of NPL was not performed; rather the documents included in 
this folder are mostly review articles which reveal the general state of the art, summarize 
available technologies, or discuss strategic approaches to immunization.  Given the rate at which 
influenza vaccine technologies have been changed, reviews were only selected from those 
published within the last five years in order to present only the most up-to-date articles. 
 
 
Appendix L:  PDF Files of This Report (electronic version only). 
 
This folder contains separate pdf files of this report and the cover to the report.  The ITTI Clinic 
wishes for this report to be as widely disseminated as possible, so that all interested parties may 
have access to the information presented herein.  However, anyone is free to base a subsequent 





Appendix M: Keywords Used in Searching. 
 
The following represents the keywords used by the team members in patent database searching.  
Note that each team member used different combinations of these terms, and only a subset of 
terms was used for any particular search. 
 
 Influenza 
o Pandemic  
 Swine 




o H{d}N{d}  (TI) 
o Orthomyxovir* (TI) Orthomyxovir! (TP) 
o HPAI (Highly Pathogenic Avian Influenza) 
o Hemagglutinin (Haemagglutinin) 
o Neuraminidase 
o Epidemic 
o !Virulen! *Virulen* 
o highly pathogenic 
o Pathogen! Pathogen* 




o Immun! (TP) Immun* (TI) 
o Immunologic! Immunologic*  
o Immunostimul! or immuno-stimul!  
o Immunomodul! or immuno-modul! 
o Immunologentic 
o Immunogen! Immunogen* 
o Immuniz! Immuniz 
o Vaccin! (TP) Vaccin* (TI) 
o Virotherap! Virotherap* 
o Prophyl! Prophyl* 
o  Antigen! Antigen* 
 Epitope! Epitope* 
 Determinant 
o Antiinfective or anti-infective (sp?) 
o Antiviral or anti-viral or anti viral 
o Viricide or Virucide 





Appendix N: Notes on Patent Families. 
 
If there are several applications or publications for an individual invention (in other countries) 
claiming the same priority or priorities and originating from the same inventors, those documents 
constitute a “patent family.”  All of the family members are related to one another by common 
priority publications with associated priority dates.  INPADOC families are organized solely on 
priority data, whereas DWPI families focus on the inventions such that divisional applications of 
a single priority document are considered to be in different patent families.  Further, Lexis 
TotalPatent reports “extended families” which are similar to INPADOC families but include 
more jurisdictions. 
 
The concept of the patent family first emerged through the Paris Convention on the Protection of 
Intellectual Property in 1883, while automated systems enabling patent family searching became 
available through the establishment of the IIB in The Hague in 1947and INPADOC in Vienna in 
1972.  Since then, patent searching has evolved due to exponential improvements in computing 
and communication technology. 
 
The term patent family can be defined in a number of ways depending on the relationship 
between a patent document and its priority or priorities within the meaning of the Paris 
Convention.  The differences only become obvious when the structure of a patent application is 
complex, i.e. when applications are filed in several countries.  Such applications may cite various 
earlier applications as priorities, or the different patent offices involved in the grant process may 
accept or refuse different patent claims.  This results in patents which have different scopes of 
protection. 
 
An important point when using any database to retrieve information on patent families is that 
there is never any guarantee that you will find all the corresponding patent documents that exist.  
Database producers do what they can to ensure completeness, but they can never guarantee it.”146 
 
The “Extended” (INPADOC) Patent Family 
 
“The biobibliographic and legal status databases form the basis of the EPO’s raw data resources 
(INPADOC).  In February 2008 the bibliographic data included about 60 million bibliographic 
data sets from almost 80 different countries.  The legal status database contains a collection of 
more than 50 million legal events from 48 countries. 
 
From the beginning, the concept was to cover as many countries and as many publication levels 
as possible.  One of the strongest motives for the integration of INPADOC into the EPO was the 
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wish to combine the particular strengths of INPADOC with the EPO’s existing in-house 
bibliographic database, “DOC-DB.” 
 
Following integration of the two databases in the 1990s, the raw data behind both databases is 
now the same.  And since esp@cenet draws on the same pool of data as raw data resources 
(INPADOC) and DOC-DB, it contains the same documentation. 
 
However, the philosophy of the “extended” (INPADOC) patent family is quite different, and so 
are the results of family searches.  Unlike the “also published as” feature in esp@cenet, which 
only shows “equivalents,” i.e. almost identical documents, an INPADOC family search should 
retrieve all documents relating in any way to the root document. 
 
Features of INPADOC 
 
When using INPADOC via one of the commercial database host services, it bears all the 
esp@cenet features, plus the following: 
 
 Standardization of applicant and inventor names 
 References to abstracts from Chemical Abstracts and Thomson Scientific 
Abstracts are made within the patent family 
 By including the legal status database additional information is available and 
additional family links can be established 
 National application numbers, international application numbers and domestic 
relations are included in the family search 
 
For both of the EPO’s raw data resources (INPADOC) and esp@cenet, even where no priority 
has been claimed by the patent application, artificial or “intellectual” links are built in systematic 
way for the complete PCT minimum documentation.  The same is done for older documents 
(pre-1968) for which the priority information is not complete. 
 
Definition of the “extended” (INPADOC) patent family 
 
All the documents directly or indirectly linked via a priority document belong to one patent 











Document D1 Priority P1   
Document D2 Priority P1 Priority P2  
Document D3 Priority P1 Priority P2  
Document D4  Priority P2 Priority P3 
Document D5   Priority P5 
 
As mentioned above, national patent application numbers, international application numbers and 
domestic relations are included in the family search. 
 
In the “extended” (INPADOC) patent family, it does not matter where a search is started.  It can 
be an application number, a priority application number or a publication number. 
If the search starts with a publication number, all application numbers, domestic application 
numbers, priority numbers and international application numbers are used to retrieve additional 
documents.  For all documents found in this step, step one is repeated.  This iteration process 
ends only when no more new documents can be found. 
 
Raw data resources (INPADOC) also use some additional sophisticated rules for certain 
countries, for example, if publication numbers are used instead of priority numbers in the 
original documents.  This happened rather frequently for older documents, where the priority 
claims were not treated as carefully as they are now.  The inclusion of legal status information in 
the patent search also sometimes retrieves additional links, e.g. for divisional applications, 
continuations, continuations in part or national publications of first filings of PCT (international) 
applications, where the priority links are often missing. 
 
Limitations of the family search in raw data resources (INPADOC) have to rely on the 
correctness of the data supplied by the co-operating patent offices and the extent to which it is up 
to date.  In particular, delays in the delivery of bibliographic data can vary significantly 
depending on the country concerned and the time period covered.  Before relying on the 
completeness of a patent family, users should check where there are gaps or delays in certain 
areas.  This kind of information can be found in the PFS and PRS statistics on the internet, which 
are updated weekly and contain indications of missing or delayed document series.  See raw data 
resources (INPADOC) useful tables and statistics.  To be absolutely sure about the actual status 
of a patent, users are recommended to contact the appropriate patent issuing authority direct.  
Particular care has to be taken in the case of European patents which have entered into the 
national phase.  The completeness and accuracy of data can vary significantly from country to 
country.  A good overview of the volume and kind of "post-grant" information available in raw 
data resources (INPADOC) can be found in the raw data resources (INPADOC) FAQ.  For most 
of the EPO member states, information about the validation, lapse, etc., of European patents is 
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given as part of the legal status information, and as mentioned before is less consistent due to the 
different quality of data available.  Starting from week 50/2007, additional post-grant 
information is taken from the fee administration system and included in the legal status part of 
the database.  
 
Thomson Scientific WPI Patent Family (DWPI)  
 
“Patent Families in the Thomson Scientific World Patents Index (WPI) draw together patents 
covering the same invention.  Their relationship is defined by the priority or application details 
claimed by each document.  Thus, in its simplest form, a new document (D1) claiming a unique 
priority (P1) will be assigned to be the basis of its own, new patent family in Thomson Scientific 
WPI.  
 
Subsequently, if a second document (D2) also claiming priority P1 is received by Thomson 
Scientific this will be added (as an ―equivalent‖) to the patent family already containing 
document D1.  Other documents claiming priority P1 will also be added to this family as 
―equivalents as they are included in the database.  Thus, a patent family may contain anything 
from a single document to 10 or more.  Each patent family represents a single record in the 
Thomson Scientific WPI database.  
 
The basic document is the first member of a patent family that appears in Thomson Scientific 
WPI, so it may not necessarily be the first one published for that invention. Differences in the 
speed that patenting authorities supply data to Thomson Scientific and in the processing time for 
documents from different countries may affect which document appears in Thomson Scientific 
WPI first and becomes basic. 
 
Patents often claim more than a single priority and these must match before any equivalent is 
added to a family.  This means that if a basic document (D3) claims priorities P2, P3 & P4, a 
subsequent document (D4) claiming priorities P2 & P3 will be added to the family as an 
equivalent, whereas patent D5 which claims priorities P2, P3 and a unique priority (P5) will form 
the basis of a new, but related patent family.  In cases such as this, the accession number of any 
related family is included in the cross-reference field of each relevant Thomson Scientific WPI 
record. 
 
Divisions and continuation patents maintain the same status as the original specification.  This 
means that if GB1 is a basic, and GB2 is divisional to GB1, then GB2 will also be a basic (in its 
own family).  However, if GB1 is equivalent to another document already in the Thomson 
Scientific WPI database, then GB2 will also join this family as an equivalent.  It should be noted 
that family relationships will be defined by the order in which patents appear in Thomson 




Thomson Scientific also puts a lot of resources into including patents in families even when no 
foreign priority is claimed, e.g. when an application has been made beyond the 12 months 
defined by the Paris Convention.  Thomson Scientific identifies these "non-convention" 
equivalents by the presence of foreign nationals and addresses in the Inventor field in the 
absence of priority data other than the local filing details.  Equivalency is determined through a 
time-consuming manual check of inventors, subject matter, etc.  
 
In this way Thomson Scientific attempts to make patent families in Thomson Scientific PI as 
comprehensive as possible.  However, because of the incidence of multiple priorities, and patent 
divisions and continuations (especially continuing applications in US documents), it is important 
to retrieve all related families through their common priorities in order to have a comprehensive 
overview of patent family relationships.”147 
 
 






The U.S. Patent Classification System is a categorization of all U.S. patent and other technical 
documents by common subject matter.  Each subject matter division includes a class and a 
subclass. The Manual of Classification is an ordered listing of all the valid classifications.  
Classes and subclasses have titles providing a general description of their contents, and 
definitions providing a more specific description.  A definition may contain an explanation of the 
class or subclass, a glossary, search notes, references to subclasses within a class, and references 
to other classes and subclasses.  The U.S. system contains about 450 classes and about 150,000 
subclasses. The classification code is express with 2 numbers separated by a forward slash, for 
example, 435/134.  The first number, 435, represents the class of the invention. The number 
following the slash, 134, is the subclass of the invention within the preceding class.  Patents will 
always have both a class and a subclass.  More explanation and definitions of U.S. patent 















 The World Intellectual Property Organization (WIPO) administers the International 
Patent Classification (IPC) system.  IPCs are organized hierarchically and divide 
technology into eight sections (A through G) with approximately 70,000 subdivisions.   
 An IPC is typically expressed as, for example, C12N 15/82, but may also appear as 
C12N001582. 
o The first letter, C, specifies a Section.   
o The number following the Section indicator, 12, specifies a Class.   
o The letter N specifies a Subclass.   
o The number 15 specifies a Main Group.   
o The number following the slash, 82, specifies a Subgroup.   
 WIPO publishes the authentic IPCs versions in English and French languages.  Chinese, 
Croatian, Czech, Dutch  German,  Hungarian,  Japanese,  Korean,  Polish,  Romanian,  
Russian,  Serbian,  and  Spanish  versions are also available.   
 More information is available at the WIPO website, 
http://www.wipo.int/classifications/ipc/en/.   
 
Description of Derwent Patent Classifications
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 The Derwent World Patent Index (DWPI) classification system categorizes patent 
documents using a simple classification system for all technologies; consistently applied 
to all patents by Thomson Scientific subject experts, enabling effective and precise 
searching in a particular area of technology. 
 International Patent Classification (IPC) is an internationally recognized classification 
system controlled by the World Intellectual Property Organization (WIPO) and assigned 
to patent documents by various patent offices. 
 Where possible Thomson indicated next to the class the equivalent IPC in an abbreviated 
form (e.g., A47, F23-5).  However, this should be used only as a guide since there are 
areas where the DWPI classes are assigned intellectually by Thomson’s subject experts, 
and no strict correspondence is claimed. 
 
 
Appendix P: Authors’ Resumes 
 
Resumes for each of the four team members follow. 
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June to Aug. Pacific Northwest National Laboratory, Richland, WA 
2004 CCI Fellowship 
Investigated “ridge-” like structures using Rutherford backscattering spectrometry, scanning electron 
microscopy, energy dispersive x-ray emission, atomic force microscopy, and high-resolution transmission 





Chico Gholz, Lisa Mandrusiak & Jeremy Barton, Spoliation in Interferences, IPToday Oct. 2012 
 
VOLUNTEER WORK 
Assistant Scoutmaster (Apr. 2008 to July 2010) 
Missionary for the LDS Church in Santa Maria, Brazil (2000 to 2002) 
 
LANGUAGES  






34A Lyndon St. 






J.D.  2013 (expected). Franklin Pierce Law Center (currently The University of New 
Hampshire School of Law), Concord, NH 
 
Ph.D.  2002. Division of Biological Sciences, University of Chicago, Chicago, IL 
 
M.S. 1996.  School of Biological Sciences, Washington State University, Pullman, WA 
 
B.S. 1992. Department of Biology, University of Illinois, Champaign, IL, cum laude 
 
LEGAL WORK EXPERIENCE 
 
Toohey Law Group, LLC., Manchester, NH 
Student Associate working exclusively for DEKA Research and Development, 2012 - current.  
 
International Technology Transfer Clinic, Concord, NH 
Project: Developing a patent landscape for pandemic influenza vaccines to assist the World 
Health Organization in the event of an outbreak.  
 
Oliff and Berridge, PLC., Alexandria, VA 
Intellectual property externship, spring semester 2013.  
 
ACADEMIC WORK EXPERIENCE 
 
Grand Valley State University, Allendale, MI 
Assistant Professor, Biomedical Sciences Department, 2009 – 2010. 
 
Centre College, Danville, KY    
Assistant Professor, Department of Biology, 2006 – 2009. 
 
Sweet Briar College, Sweet Briar, VA    
Assistant Professor, Department of Biology, 2002 – 2006. 
 
Each position involved designing and teaching courses as the sole instructor. Subjects taught 
include human anatomy and physiology, comparative anatomy, comparative physiology, 
genetics, general biology, and scanning electron microscopy. I established a research lab, 
conducted research as the principal investigator, and supervised student research. I wrote and 
received external grants, and published primary research in peer-reviewed journals. I directed the 





SELECTED PUBLICATIONS and MEETING PRESENTATIONS 
 
2005 Janovetz, J. Functional Morphology of Feeding in the Scale-eating Specialist, Catoprion 
mento. Journal of Experimental Biology 208: 4757 – 4768. 
 
2005 Janovetz, J. Society of Integrative and Comparative Biology, San Diego, CA. Functional 
Morphology of Prey Capture in Serrasalmine Fishes. American Zoologist 44:30.10A.  
 
2005 Lambert*, B., and J. Janovetz. Mid-Atlantic Regional Conference of Undergraduate 
Scholarship, Sweet Briar, VA. Feeding Kinematics and Jaw Protrusion in the Creek Chub, 
Semotilus atromaculatus.  
 
2005 Janovetz, J. American Society of Ichthyologists and Herpetologists, Tampa, FL. 
The Kinematics of Biting Prey Capture in Pacus, Silver Dollars, and Piranhas.  
 
2004 Janovetz, J. Society of Integrative and Comparative Biology, New Orleans, LA. 
Functional Morphology of Feeding in the Scale-eating Piranha, Catoprion mento. American 
Zoologist, 43:30.8A.  
 
2003 McGuffey*, S., and J. Janovetz. Mid-Atlantic Regional Conference of Undergraduate 
Scholarship, Sweet Briar, VA. The Effects of Pavlovian Conditioning on the Anti-predator 
Behavior of Hognose Snakes. 
 
2002 Janovetz, J. Society of Integrative and Comparative Biology, Anaheim, CA. 
Biomechanics of Feeding in a Scale-eating Piranha: A Novel Feeding Behavior Using Extreme 
Jaw Rotation and Momentum Transfer. American Zoologist 41:10.1A. 
 
2002 Janovetz, J. Functional and Ecological Morphology of Feeding in Pacus, Silver Dollars, 
and Piranhas (Serrasalminae: Teleostei). Ph.D. thesis, University of Chicago.  
 
2001     Alfaro, M.E., J. Janovetz, and M.W. Westneat. Motor Control across Trophic Strategies: 
Muscle Activity of Biting and Suction Feeding Fishes. American Zoologist 41(6):1266-1279.  
 
1999  Janovetz, J. Society of Integrative and Comparative Biology, Regional Meeting, Athens, 
OH. Evolution of Feeding Behavior in Serrasalmine Fishes. Best Student Paper award. 
 
* denotes undergraduate co-author 
 
PROFESSIONAL ACTIVITIES  
Include reviewing and editing manuscripts for The Biological Journal of the Linnaean Society, 
Animal Behavior, Philosophical Transactions Royal Society London B, Behavioral Ecology and 




John Schroeder                                                                            104 Pleasant St. Concord, NH 03302  
(918) 688-2094             John.Schroeder@law.unh.edu 
 
Education 
University of New Hampshire School of Law, Concord, NH 
Juris Doctor Candidate, May 2014 
Activities:  
International Technology Transfer Clinic 
Current member of Student Intellectual Property Law Association 
Current parliamentarian of the Black Law Student Association 
 
Hendrix College, Conway, AR 
Bachelor of Arts in History and Biology, January 2011 
Activities: 
Teaching Assistant for Zoology Laboratory, fall term of 2009  
Teaching Assistant for Botany Laboratory, spring terms of 2009 and 2010          
Laboratory Assistant for Cell Biology, fall term of 2008                                              
Experience 
New Hampshire District Court Circuit Court Division –Internship June 2012 – Present 
 Assisted in updating the New Hampshire judicial bench book, a manual containing the 
current New Hampshire jurisprudence designed to assist new judges in all areas of law.  
Hendrix College - Assistant Laboratory Technician for Dr. Jennifer Dearolf   May 2010 - December 
2010  
 Analyzed the percentage of different myosin isoforms present in the scalenus muscle of fetal 
guinea pigs. 
 Responsible for gathering and interpreting data collected by eight former lab assistants 
necessary for publication of professor’s findings. 
Hendrix College- Summer Laboratory intern for Dr. Jennifer Dearolf, May 2009- May 2010                                                       




 Co-President of The Hendrix College chapter of Habitat for Humanity, 05/10 - 12/10 
 
Presentations and Publications 
 Co-author of presentation, Effects of prenatal steroids on myosin heavy chain expression of 
breathing and locomotor muscles. SE Regional IDeA Meeting - September 22-24, 2011, 
New Orleans, LA 
 Oral Presentation of The effects of glucocorticoids on myosin expression patterns of fetal 
Cavia porcellus hindlimb and ventilatory musculature at the Society for Integrated and 
Comparative Biology 2011 Annual Meeting - January 3-7, 2011, Salt Lake City, Utah  
 Poster Presentation of The effects of betamethasone on myosin expression patterns of fetal 
Cavia porcellus rectus thoracis and scalenus muscles at Third Biennial National IDeA 
Symposium - June 16-18, 2010, Washington DC, 2010 
 Poster Presentation of The effects of betamethasone on myosin expression patterns of fetal 
Cavia porcellus rectus thoracis muscle at the Society for Integrated and Comparative 
Biology 2010 Annual Meeting - January 3-7, 2011, Seattle, WA, 2010 
